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STUDY SUMMARY 
Title IPT in schoolchildren: Comparison of the efficacy, safety, and tolerability 
of antimalarial regimens 
Study design Randomized, single-blinded, placebo controlled trial 
Participants and 
sample size 
Children aged ≥ 8 years attending primary schools 
The initial target sample size is 760 children (190 per study arm)  
Study site The study will be conducted at one of the Uganda Malaria Surveillance Project 
(UMSP) sentinel sites in Tororo, an area with high transmission intensity 
Selection 
criteria 
Inclusion criteria 
1. Age > 8 to < 14 years (boys); > 8 to < 12 years (girls) 
2. Student enrolled at participating school in classes 1 to 7 
3. Provision of  informed consent from parent or guardian 
4. Provision of assent by student 
Exclusion criteria 
1. Known allergy or history of adverse reaction to study medications 
2. Onset of menstruation (girls) 
3. Fever (> 37.5ºC axillary) or history of fever in the previous 24 hours 
4. Evidence of severe malaria or danger signs 
5. Ongoing antimalarial treatment 
6. Haemoglobin < 7.0 g/dL 
7. Parasite density > 10,000/ul 
Study 
intervention 
Participants will be randomized to one of four treatment arms and followed for 42-d:  
1. Sulfadoxine-pyrimethamine (SP) 
2. Amodiaquine + sulfadoxine-pyrimethamine (AQ+SP) 
3. Dihydroartemisinin-piperaquine (DP) 
4. Placebo 
Participants in the SP arm will also receive placebo tablets on days 1 and 2 to ensure 
that the number of doses received is identical in the other treatment groups.  
Primary 
objective 
To compare the efficacy of different combination antimalarial regimens, including 
AQ+SP, DP, and placebo to SP for IPT in schoolchildren, as measured by risk of 
parasitaemia (unadjusted by genotyping) after 42 days of follow-up.  This will assess 
both the efficacy for treatment of asymptomatic infections and the efficacy for 
prevention of new infections. 
Secondary 
objectives 
1. To compare the efficacy of different antimalarial regimens, including AQ+SP and 
DP, to SP for treatment of asymptomatic infection, as measured by risk of 
recurrent parasitaemia (adjusted by genotyping) in children who were parasitaemic 
at enrollment. 
2. To compare the efficacy of different antimalarial regimens, including AQ+SP and 
DP, to SP for prevention of new infections, as measured by risk of recurrent 
parasitaemia (adjusted by genotyping) in all children. 
3. To compare the safety and tolerability of SP, AQ+SP, and DP to that of placebo 
for IPT in schoolchildren, over 42 days of follow-up.   
4. To evaluate the acceptability of the different IPT regimens by study participants. 
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LIST OF ABBREVIATIONS AND ACRONYMS 
 
ACT  artemisinin-based combination therapy 
ACPR  adequate clinical and parasitological response 
AE  adverse event 
AL  artemether-lumefantrine 
AS  artesunate  
AQ  amodiaquine   
CF  clinical failure 
DOMC Division of Malaria Control 
DP  dihydroartemisinin-piperaquine 
DSMB  data safety and monitoring board 
GCP  good clinical practices 
Hb  haemoglobin 
IMCI  integrated management of childhood illnesses 
IPT   intermittent preventive treatment 
ITN  insecticide treated net 
IRB  institutional review board 
HIV  human immunodeficiency virus 
HPLC  high performance liquid chromatography 
LMP  last menstral period 
LSHTM London School of Hygiene & Tropical Medicine 
MoH  Ministry of Health (Uganda Government) 
MU  Makerere University (Kampala, Uganda) 
PF  parasitological failure 
SAE  serious adverse event 
SP  sulfadoxine-pyrimethamine 
UCSF  University of California, San Francisco 
UMSP  Uganda Malaria Surveillance Project 
UNCST Uganda National Council of Science and Technology 
VCD  Vector Control Division, Ugandan Ministry of Health 
WHO  World Health Organization 
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1.0  BACKGROUND 
 
1.1 Introduction 
Malaria remains one of the most serious global health problems.1 It is estimated that 
between 400 to 900 million episodes of fever occur yearly in African children, probably 
about half due to malaria, resulting in over one million deaths.2,3 In Africa, severe 
anaemia is a major contributor to malaria-associated death.4,5  In addition to acute illness, 
chronic manifestations of malaria, including anaemia, neurocognitive dysfunction, 
developmental delay, and pregnancy-related complications, contribute substantially to the 
clinical impact and burden of disease.6 Despite recent commitments to control malaria in 
Africa, it appears that malaria-specific mortality is rising, accounting for an increasing 
proportion of overall childhood morality.7 Typically, malaria control efforts focus on 
children under five years (and pregnant women) because they bear the brunt of morbidity 
and mortality.  In endemic areas, risk of clinical disease and death declines throughout 
childhood due to the gradual acquisition of immunity gained through repeated infection.8 
By adolescence, most malaria infections are asymptomatic, although pregnancy again 
places women at increased risk. While older children generally suffer less mortality and 
morbidity, malaria in this age group is not insignificant, and is of substantial importance 
to education of schoolchildren through reduced school attendance, cognition, learning 
and school performance.9   
 
1.2 Burden of malaria in Uganda 
Malaria is endemic in 95% of Uganda, and is the leading cause of morbidity and 
mortality in the country, accounting for 25-40% of all outpatient visits at health facilities, 
20% of hospital admissions, and 9-14% of inpatient deaths (Uganda Ministry of Health, 
unpublished). In Uganda, and many countries in sub-Saharan Africa, malaria remains one 
of the leading causes of death amongst children under five years.10 In addition, a recent 
information update on malaria in Uganda from the Ministry of Health (2000) reported 
that malaria morbidity is increasing (25-40% of outparticipant visits in 1992-3, 27-51% 
in 1998 and 29-50% in 1999). 
 
1.3 Intermittent preventive treatment 
Intermittent preventive treatment (IPT), the administration of curative doses of anti-
malarial treatment at predefined intervals regardless of infection status, is recommended 
to reduce malaria in pregnancy.11  Studies of IPT with sufadoxine-pyrimethamine (SP) 
have demonstrated that treatment reduces the negative impact of malaria in pregnancy, 
including placental parasitaemia, maternal anaemia, parasite prevalence, and low birth 
weight.12-19  In Uganda, IPT in pregnancy (IPTp) has been adopted as policy, with the 
recommendation that all pregnant women receive a treatment dose of SP in the second 
and third trimester (http://www.health.go.ug/mcp/mp.html). Given the benefits of IPT in 
pregnant women, use of IPT is also being investigated among infants (IPTi) and young 
children (IPTc), and has been shown to reduce anaemia and clinical malaria episodes.20-24 
Although intermittent treatment of malaria has been shown to be beneficial, the method 
by which IPT exerts its action is unclear.25 IPT may treat unrecognized infection in 
asymptomatic individuals who would typically go untreated, and may also prevent new 
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infections by providing post-treatment prophylaxis. Prevention of new infections may be 
the more important factor, particularly in areas of high transmission intensity.25   
 
1.4 IPT in schoolchildren 
In Africa, children under five and pregnant women are typically considered to be at 
highest risk of malaria-associated morbidity and mortality. However, older children are 
also at risk, particularly for the chronic effects of malaria infection.9 Currently, use of IPT 
among schoolchildren as a method to improve haemoglobin status and school 
performance through prevention of malaria and treatment of asymptomatic infection is 
also being explored. Results from a recent trial of IPT, investigating use of amodiaquine 
+ sulfadoxine-pyrimethamine (AQ+SP) in Kenyan schoolchildren found that thrice 
yearly IPT (administered once each term) reduced the absolute risk of malaria by 0.36 
(95% CI 0.31 to 0.41) and anaemia by 0.07 (95% CI 0.02 to 0.12) (Clarke et al, 
unpublished data). Treatment was also associated with a significant improvement in 
cognitive performance (Clarke et al, unpublished data). These findings hold promise for 
an effective school-based malaria control strategy. 
 
1.5 Role of the education sector 
The potential role of the education sector in malaria control, through prevention and 
treatment, is gaining attention.26-28 Recently, the World Health Organization published a 
report on malaria prevention and control in schools, which highlights the potential role of 
the education sector in malaria control and supports action on malaria in schools.29 
Although there is interest in expanding malaria control activities to schools, guidelines 
and policies on how to implement prevention and treatment programmes in practice are 
limited. To help fill this information gap, the World Bank has recently supported an 
initiative to strengthen the ability of the education sector to address the impact of malaria 
on school-aged children, and to provide guidelines for incorporating a school-based 
malaria response, possibly including IPT, into education projects (Simon Brooker, 
personal communication).  
 
1.6 Choice of drugs for IPT 
Although IPT has become an important part of malaria control, the optimal regimen 
remains unclear.25 When assessing regimens for IPT, factors to consider include the 
effectiveness, which incorporates drug efficacy, ease of administration, cost, availability, 
and acceptability, and safety and tolerability.30 Determinants of the efficacy of an IPT 
regimen include the ability to successfully treat unsuspected infection, and the ability to 
prevent new infections by providing post-treatment prophylaxis.25 The availability of co-
formulated drugs for combination regimens, and the likelihood of proper administration 
and adherence also contribute to effectiveness. Considering these factors, the ideal IPT 
regimen would be highly efficacious, long-acting, and easy to administer. However, 
balancing these factors is challenging, and the benefits of long-acting drugs in preventing 
reinfection must be weighed against the potential risk of driving drug resistance.31 Cost, 
availability, and acceptability are also important, particularly for programme 
effectiveness, and all factors should be considered when selecting a regimen for IPT. 
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1.7 IPT regimens 
All antimalarial regimens used for treatment of uncomplicated malaria are options for 
IPT, including older monotherapies and newer combination regimens.  
 
1.7.1 Sulfadoxine-pyrimethamine (SP). Of the available regimens, SP has been most 
widely studied for IPT. Currently SP is recommended for IPT in pregnant women, and is 
the only regimen included in an IPT policy in Uganda and many other African countries. 
SP has several advantages that make it attractive for use in an IPT program in 
schoolchildren, including low cost, wide availability, simple dosing and relatively long 
elimination half-life (Table 1) . The fact that SP is administered as a single dose ensures 
100% adherence with each treatment, which could have a substantial impact on 
operational effectiveness of IPT. However, resistance to SP has become widespread in 
Africa, which could limit the utility of this regimen.25  Regarding efficacy of SP, 
although the rate of failure when SP is used for treatment of symptomatic malaria is high, 
the efficacy of SP for treatment of asymptomatic infections and prevention of new 
infections is unknown. It is also possible that acquired immunity in older children will 
complement drug action and may compensate for drug resistance. It is thus possible that 
SP may retain its efficacy in such a situation, which needs further investigation. The 
advantages of SP would therefore make it the ideal therapy for use in IPT in 
schoolchildren, and the efficacy, safety and tolerability of the other regimens will need to 
be compared to SP.  
 
1.7.2 Amodiaquine + sulfadoxine-pyrimethamine (AQ+SP). AQ alone, and in 
combination with SP have previously been evaluated for IPT.22 By adding AQ to SP, 
efficacy is significantly improved, but the dosing becomes more complex, extending to a 
three-day treatment.32 In schoolchildren, AQ+SP for IPT was found to achieve 92% 
parasitological clearance by day 28 post-treatment in Western Kenya, an area with high 
levels of SP-resistance (Clarke et al, unpublished data).  
 
1.7.3 Artemisinin combination therapies (ACTs). Newer ACTs are also potential 
options for IPT, including AQ plus artesunate (AQ+AS), artemether-lumefantrine (AL, 
Coartem), and AS+SP. Generally, ACTs are highly efficacious; however, the very short 
half-life of artemisinin derivatives offers no post-treatment prophylaxis. Artemisinins are 
rapidly eliminated leaving the partner drug to act on its own, which is a potential 
downside for all ACT regimens in IPT.25 AL has been shown to be highly efficacious, 
and to prevent more new infections than AQ+AS, 33 but the twice daily dosing of AL is a 
significant disadvantage for IPT.  Both AL and AQ+AS have also been selected as first-
line therapy for uncomplicated malaria in newly revised antimalarial policies in most 
African countries (http://www.who.int/malaria/amdp/amdp_afro.htm), which may 
dissuade policy-makers from incorporating these regimens into IPT programmes.  AS+SP 
has been investigated for IPT in children in Senegal,23 however, the high level of SP 
resistance in much of Africa may also limit use of this regimen. A new co-formulated 
ACT, dihydroartemisinin-piperaquine (DP), is a very attractive option for IPT.  DP is 
highly efficacious and is dosed once daily. The long terminal half-life of piperaquine 
provides extended post-treatment prophylaxis, and a study comparing DP to AL for 
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treatment of uncomplicated malaria in Uganda showed that DP was superior for 
prevention of new infections in an area of intense transmission (Kamya et al, in press).     
 
 
Table 1. Possible IPT regimens: Comparison of efficacy  
for treatment of uncomplicated malaria with 28-day follow-up 
Efficacy: treatment of 
uncomplicated malaria 
Post-treatment 
prophylaxis 
Ease of 
administration 
Regimen Site and 
transmission 
intensity34 Risk of 
treatment 
failure 
Risk of 
recurrent 
parasitaemia*  
Terminal half-life in 
health25 
Dosing schedule 
SP † >34% >88% sulfadoxine 7 days 
pyrimethamine 3 days 
Single dose 
AQ+SP 18% 59% amodiaquine 1-3 weeks? 
sulfadoxine 7 days 
pyrimethamine 3 days 
Once daily for 
three days 
AQ+AS 
Tororo35 
EIR = 562 
2002-2004 
 12% 74% amodiaquine 1-3 weeks? 
artesunate 1 hour 
Co-formulated 
Once daily for 
three days 
AL Tororo33 
EIR = 562 
2004-2005 
1% 51% artemether 1 hour  
lumefantrine 3-4 days 
Co-formulated  
Twice daily for 
three days 
AS+SP Kampala 36 
EIR < 5 
2001-2002 
18% 29% artesunate 1 hour  
sulfadoxine 7 days 
pyrimethamine 3 days 
Once daily for 
three days 
DP ‡ Apac 
(Kamya, in 
press) 
EIR = 1586 
2006 
2% 11% dihydroartemisinin 1 
hour  
piperaquine 22 days 
Co-formulated 
Once daily for 
three days 
* Including risk of new infections 
† Efficacy results for SP extrapolated from data collected for CQ+SP 
‡ In this study, ITNs were distributed at the time of enrollment, which likely decreased the risk of new infections. 
 
 
1.8 Safety and tolerability of IPT regimens 
Safety and tolerability of IPT regimens is a key issue. Typically, the safety and 
tolerability of antimalarial regimens is assessed in clinical trials by evaluating treatment 
of symptomatic cases, often in very young children. However, antimalarial therapy 
delivered through IPT programmes will generally be administered to asymptomatic 
children and pregnant women.  Use of poorly tolerated therapy for IPT in asymptomatic 
children is likely to be less acceptable than use of the same treatment for symptomatic 
malaria. Older asymptomatic children may be more capable of observing and reporting 
adverse effects of treatment, enabling fuller documentation and quantification of adverse 
effects.  
 
All IPT regimens under consideration have been shown to be relatively safe and well-
tolerated.  However, there are concerns about the lower tolerability of AQ and AQ+SP.  
In Rwanda, adult participants treated for uncomplicated malaria with AQ or AQ+SP 
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more commonly reported pruritis and fatigue than those treated with SP alone.37 An 
additional study from Rwanda indicated that the risk of adverse events was lower with 
DP than AQ-containing regimens.38 In the Kenyan trial of IPT with AQ+SP in 
schoolchildren, anecdotal reports suggest that this combination was associated with a 
range of mild adverse events, including nausea, weakness and fatigue, which may 
influence future adherence and acceptability of the intervention (Clarke, unpublished 
data). Tolerability of available antimalarials among asymptomatic schoolchildren is 
therefore a key research question that needs to be addressed prior to undertaking large-
scale effectiveness studies of IPT.  
 
 
2.0 RATIONALE 
 
IPT in pregnancy has become an important component of malaria control in Africa.39 IPT 
programmes may also benefit infants and children,24,40 and delivery of IPT to children in 
schools provides an opportunity to extend malaria control activities to older children. 
Studies of the efficacy, safety, and tolerability of antimalarial therapy are typically 
conducted in symptomatic malaria participants. As a result, the published literature on the 
efficacy and safety of antimalarial regimens may not be generalisable to asymptomatic 
individuals, and additional research is essential.  In addition, the mechanism of action of 
IPT is uncertain, and assessment of the impact of IPT on treatment of asymptomatic 
infection, and prevention of new infections is needed.  
 
Although IPT shows promise as an approach to malaria control in schools, the optimal 
regimen remains unclear.  We propose to compare the efficacy, safety and tolerability of 
different antimalarial regimens in schoolchildren, anticipating that this study will be a 
‘pilot’ for future IPT research. We plan to evaluate SP, AQ+SP, DP and placebo in 
healthy schoolchildren, regardless of infection status. The efficacy of the combination 
regimens will be compared to that of SP, and the safety and tolerability of all regimens 
will be compared to that of placebo.  From our experience, assessment of the safety and 
tolerability of antimalarial treatment in African children is complicated by the overlap 
between common adverse events, symptoms of malaria, and symptoms of common non-
malarial illnesses. The inclusion of the placebo arm will allow us to assess the risk of 
adverse events with each of the regimens, as compared to no treatment.  
 
 
3.0 STUDY OBJECTIVES  
 
3.1 Primary objective: 
 
To compare the efficacy of different combination antimalarial regimens, including 
AQ+SP, DP, and placebo, to SP for IPT in schoolchildren, as measured by risk of 
parasitaemia (unadjusted by genotyping) after 42 days of follow-up.  This will 
assess both the efficacy for treatment of asymptomatic infections and the efficacy 
for prevention of new infections. 
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3.2 Secondary objectives: 
 
1. To compare the efficacy of different antimalarial regimens, including AQ+SP and 
DP, to SP for treatment of asymptomatic infection, as measured by risk of 
recurrent parasitaemia (adjusted by genotyping) in children who were 
parasitaemic at enrollment. 
 
2. To compare the efficacy of different antimalarial regimens, including AQ+SP and 
DP, to SP for prevention of new infections, as measured by risk of recurrent 
parasitaemia (adjusted by genotyping) in all children. 
 
3. To compare the safety and tolerability of SP, AQ+SP, and DP to that of placebo 
for IPT in schoolchildren, over 42 days of follow-up.   
 
4. To evaluate the acceptability of the different IPT regimens by study participants. 
 
 
4.0 STUDY DESIGN 
 
4.1 Overall study design 
This will be a randomized, single-blinded, placebo-controlled trial to evaluate the 
efficacy, safety and tolerability of antimalarial regimens in healthy schoolchildren. The 
study will be carried out among children aged ≥ 8 years (to < 14 years for boys, and to < 
12 years for girls) attending primary schools in Tororo district.  Schools will be selected 
using convenience sampling with the assistance of the district and the education sector.  
The target population includes children attending primary schools in Uganda.  The 
accessible population includes the children attending the participating primary schools in 
classes 1 to 7 in Tororo district.  Children who meet the selection criteria for participation 
in the study will be randomized to treatment with one of the four study regimens and will 
be followed for 42 days.  Repeat evaluations will be performed on days 1, 2, 3, 7, 14, 28, 
and 42 (and any unscheduled day that a student is ill) and will include assessment for the 
occurrence of adverse events. Treatment efficacy outcomes will be assessed using revised 
WHO outcome classification criteria.41 Acceptability of treatment regimens will be 
assessed using a questionnaire administered to participating students on day 7.  
 
4.2 Classification of treatment outcome 
Response to treatment will be classified according to criteria modified from the 2006 
WHO system for classification of outcome following treatment for uncomplicated 
malaria, and will include clinical failure (CF), parasitological failure (PF), and adequate 
clinical and parasitological response (ACPR).41   
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Table 2. Classification of treatment outcome 
Clinical failure: Days 0 to 42 
 Development of danger signs or severe malaria on Days 0 to 42 in the presence of parasitaemia* 
 Temperature > 37.5C (axillary), or history of fever in previous 24 hours, on Days 3 to 42 in the 
presence of parasitaemia* 
Parasitological failure: Days 3 to 42 
 Development of hyperparasitaemia (> 10,000/ul) on Days 1 to 42* 
 Presence of parasitaemia on Days 4 to 41 and axillary temperature  < 37.5C, without previously 
meeting any of the criteria of clinical failure 
 Presence of parasitaemia on Day 42 and axillary temperature  < 37.5C, without previously 
meeting any of the criteria of clinical failure* 
Adequate clinical and parasitological response: Day 42 
 Absence of parasitaemia on Day 42 irrespective of temperature without previously meeting any 
of the criteria for clinical failure or parasitological failure 
* Requires rescue antimalarial therapy 
 
For all clinical and parasitological failures, molecular genotyping will be used to 
distinguish recrudescence from new infection (see section 8.3). In the final analysis, 
treatment outcomes will be dichotomized based on the following definitions:  
 
 Risk of parasitaemia = CFs + PFs (unadjusted by genotyping) 
 Clinical failure = All CFs due to recrudescence (adjusted by genotyping) 
 Parasitological failure = All PFs due to recrudescence (adjusted by genotyping) 
 
4.3 Outcome measures 
 
4.3.1 Primary outcome. Risk of parasitaemia (unadjusted by genotyping) after 42 days 
of follow-up  
4.3.2 Secondary outcomes 
1. Risk of recrudescence (adjusted by genotyping) in children who were 
parasitaemic at enrollment, after 42 days of follow-up  
2. Risk of new infection (adjusted by genotyping) in all children 
3. Risk of clinical failure due to recrudescence (adjusted by genotyping) in children 
who were parasitaemic at enrollment, after 42 days of follow-up 
4. Risk of parasitological failure due to recrudescence (adjusted by genotyping) in 
children who were parasitaemic at enrollment, after 42 days of follow-up 
5. Mean haemoglobin at day 42 
6. Mean change in haemoglobin between day 0 to day 42 
7. Risk of serious adverse events over 42 days of follow-up 
8. Risk of all adverse events after 14 and 42 days of follow-up 
9. Acceptability of IPT regimens 
 
 
 
 
 IPT in schoolchildren, Version 1.3, 17 March 2008 
 
14 
5.0 PARTICIPANT SELECTION AND ENROLLMENT 
 
5.1 Study site 
The study will be conducted among schoolchildren in Tororo district, an area with high 
malaria transmission intensity (estimated entomologic inoculation rate of 586 infective 
bites per person-year).34 The prevalence of malaria infection among primary 
schoolchildren in Tororo is 51%, and 19% of children are anaemic (Simon Brooker, 
personal communication). Hookworm is also common, with 42% of children infected.  
Information on primary schools from West Budama North school district in Nagongera 
sub-county in Tororo is provided in Table 3. 
 
 
Table 3. Primary schools in Nagongera sub-county 
School Estimated distance from 
Nagongera health center 
Enrollment 
Rock Hill < 1 km 1110 
Nagongera Girls 1.5 km 1151 
St. Joseph Nagongera 3 km 787 
Mahanga 3 km 532 
Maundo 3 km 832 
Bishop Yona Okoth Memorial 3 km 1026 
Pokongo Rock 4 km 931 
Namwaya 2.5 km 892 
Okwira 3.5 km 903 
Walaweji 3 km 799 
Mukwana 3 km 659 
Soni Ogwangi 6 km 240 
Pagoya 4km 687 
Matindi 4km 553 
Total enrollment 11,102 
 
 
The study will be conducted by the Uganda Malaria Surveillance Project (UMSP) in 
collaboration with the Uganda Vector Control Division and the London School of 
Hygiene and Tropical Medicine.  UMSP was established in 2001 to enhance local 
research capacity and expand existing infrastructure with the goal of providing 
sustainable progress in malaria control in Uganda. UMSP has extensive expertise and 
experience in collecting “state of the art” drug efficacy data in studies with large sample 
sizes, extended follow-up, use of molecular genotyping to distinguish recrudescence from 
new infections, systematic collection of data on drug safety and tolerability, and quality 
control.  
 
 
5.2 Selection criteria 
Children enrolled in participating schools will be assessed for the following eligibility 
criteria: 
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5.2.1 Inclusion criteria 
1. Age ≥ 8 to < 14 years (boys); ≥ 8 to < 12 years (girls) 
2. Student enrolled at participating school in classes 1 to 7 
3. Provision of informed consent from parent or guardian 
4. Provision of assent by student 
 
5.2.2 Exclusion criteria:  
1. Known allergy or history of adverse reaction to study medications 
2. Onset of menstruation (girls) 
3. Fever (≥ 37.5°C axillary) or history of fever in the previous 24 hours 
4. Evidence of severe malaria or danger signs 
5. Ongoing antimalarial treatment 
6. Haemoglobin < 7.0 gm/dL 
7. Parasite density > 10,000/ul 
 
5.3  Initial recruitment and consent 
Schools in Tororo district will be selected using convenience sampling with the 
assistance of the district and the education sector. Prior to the onset of the study, staff 
from participating schools will be sensitized about the study and plans for recruitment 
and follow-up. Group meetings will then be held with the parents/guardians of 
schoolchildren aged > 8 to < 14 years (boys); ≥ 8 to < 12 years (girls), who are enrolled 
in classes 1 to 7 (Appendix A). The group meetings will be held at a convenient location 
within the community. During the meetings, the purpose and procedures of the study will 
be discussed, an information sheet will be distributed (Appendix B), and written informed 
consent will be sought from the parents/guardians (section 10.2). Consent to participate in 
the research study and consent for future use of biological specimens will be sought 
(Appendix C). Information about all children, including age, gender, any history of 
known allergies or adverse reactions to study medications, and onset of menstruation in 
girls will be obtained from parents/guardians and captured on an initial screening form 
(Appendix D), but only children for whom consent is provided will have a study number 
assigned, and will undergo further clinical screening at school (Appendix E). Details 
about the location of the students’ homes will also be obtained from the parent/guardians 
to facilitate tracing in the event of absence from school on subsequent follow-up visits.  
 
5.4 Screening and enrollment of schoolchildren 
Further clinical screening will be conducted at the participating schools (Appendix E). 
Assessment for eligibility will be done by the study physicians, and interviews will be 
conducted in the appropriate language with the schoolchildren. During the screening 
process, the study physicians will assess for eligibility criteria (including onset of 
menstruation in girls) through conversations with the student, and will seek assent from 
the student to participate in the study (Appendix F).  Children meeting these criteria will 
undergo a history and physical examination, including measurement of temperature. 
Children will specifically be evaluated for evidence of clinical conditions requiring 
treatment, including presence of fever or history of fever, or evidence of danger signs or 
severe malaria (Table 4). In such situations, children will be excluded and treated 
appropriately. If there is evidence of severe illness, children will be referred for 
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additional evaluation and treatment. In addition, children currently receiving antimalarial 
treatment will be excluded.  
 
Table 4. Danger signs / Severe malaria 
 Unarousable coma (if after convulsion, > 30 min) 
 Repeated convulsions (> 2 within 24 h) 
 Recent convulsions (1-2 within 24 h) 
 Altered consciousness (confusion, delirium, psychosis, coma) 
 Lethargy 
 Unable to drink 
 Vomiting everything 
 Unable to stand/sit due to weakness 
 Severe anaemia (Hb < 5.0 gm/dL) 
 Respiratory distress (labored breathing at rest) 
 Jaundice (yellow colouring of eyes) 
 
Children fulfilling the clinical selection criteria will have a fingerprick blood sample 
obtained for haemoglobin measurement, for thick and thin blood smear, to save a 
bloodspot on filter paper for future molecular testing, and to assess for prior antimalarial 
treatment by high performance liquid chromatography (see section 8.4 for details of 
laboratory evaluations). Children with a haemoglobin level < 7.0 g/dL will be excluded 
and treated appropriately. After blood is obtained by fingerprick, the students will be 
referred to the study nurse for treatment allocation and treatment with the study 
medications. A standardized assessment will be carried out to document the presence and 
severity of symptoms present on the day of treatment (Appendix G). This standardized 
assessment will be used as the baseline for monitoring of any future adverse events 
(Appendix H and K). On day 0, the child will be given a study identification card, 
indicating the dates of scheduled follow-up assessments. On day 0, a stool sample will 
also be collected to assess for the presence and intensity of helminth infections.  Results 
of the Giemsa-stained thick and thin blood smears obtained on day 0 will not be available 
until after the children have been treated. Enrollment will be finalized on day 1 when the results 
of the thick blood smears are available. Students will return for evaluation on day 1 and will be 
excluded from the study, and treated appropriately, if the parasite density is > 10,000/ul.  
 
 
6.0 STUDY INTERVENTION 
 
6.1 Randomization 
Computer generated randomization lists will be created by a member of the project who 
will not be directly involved in the conduct of the study. Sealed copies of the original 
randomization lists and documentation of the procedure used to generate the lists will be 
stored in the project administrative offices in Kampala.  Prior to the onset of the study, 
sealed copies of the randomization lists will be distributed to the study nurse responsible 
for treatment allocation. 
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6.2 Treatment assignment and allocation 
Participants will be randomly assigned to one of the four treatment arms (SP, AQ+SP, 
DP, or placebo). Randomization will be done according to the pre-determined 
randomization list. Treatment assignment and administration of medications will be 
performed by the study nurse. To allocate participants to the appropriate treatment group, 
the study nurse will select the next available treatment number and corresponding study 
regimen. The study nurse will record the date and time of treatment assignment and the 
participant's study number.   
 
6.3 Study treatments 
 
 
Table 5. Drug formulation and labeling 
Regimen Trade name (Manufacturer) Class 
Sulfadoxine-pyrimethamine 
(500mg/25mg) 
Fansidar / Roche Antifolate combination 
Amodiaquine (200mg) Camoquin / Pfizer (formerly 
Parke-Davis) 
4-aminoquinoline 
Dihydroartemisinin-
piperaquine (40mg/320mg) 
Duocotexcin / Holley-Cotec 
Pharmaceuticals 
Artemisinin derivative + 
bisquinoline 
 
 
6.4 Dosing of study drugs 
All participants will receive one dose of medication for 3 days. Study medications will be 
administered according to weight-based guidelines (Appendix I). Dosing of SP is based 
on the sulfa component, and the dosing of placebo will mimic that of AQ (10 mg/kg 
daily). 
 
 
Table 6. Treatment administration 
Treatment group Day 0 Day 1 Day 2 
SP SP (25 mg/kg) Placebo  Placebo 
AQ (10 mg/kg) AQ (10 mg/kg) AQ (10 mg/kg) AQ+SP 
SP (25 mg/kg sulfa) ― ― 
DP DP  (2.1/17.1 mg/kg) DP (2.1/17.1 mg/kg) DP (2.1/17.1 mg/kg) 
Placebo Placebo Placebo Placebo 
 
 
6.5 Blinding 
Study medications will not be identical in appearance or taste, but the number of doses 
received will be similar for children in all treatment groups. Participants will not be 
informed of their treatment regimen, and all study staff involved in the assessment of 
participant outcomes, including the study clinicians (responsible for clinical assessment 
and measurement of temperature) and laboratory technicians (responsible for reading 
thick blood smears and determining parasite density) will be blinded to the treatment 
group assignments 
 
 IPT in schoolchildren, Version 1.3, 17 March 2008 
 
18 
6.6 Administration of study drugs 
All study drugs will be administered by the study nurses at the schools.  Treatment will 
be directly observed. The study nurse will record the date and time study drugs are 
administered. Study drugs will be given as tablets or fractions of tablets to be taken orally 
with a glass of water. The study nurse will directly observe consumption of study drug. 
Participants will be observed for 30 minutes to ensure that the medications are not 
vomited. Any participant who vomits the medication within 30 minutes of administration 
will be retreated with a second dose. Any participant who vomits repeatedly (> 3 times) 
will be classified as a clinical failure based on evidence of danger signs (Table 2) and will 
be referred for further evaluation and appropriate treatment.  
 
 
7.0  FOLLOW-UP EVALUATION AND PROCEDURES 
  
7.1 Scheduled follow-up procedures 
All participants will be followed for 42 days. Repeat evaluations will be done at the 
school on days 1, 2, 3, 7, 14, 28, and 42, and any unscheduled day that a participant is ill, 
which will involve obtaining blood samples to evaluate efficacy outcomes, and 
monitoring the occurrence of adverse events. At each repeat visit, temperature will be 
measured and a focused physical examination will be performed.  If the child is febrile 
(axillary temperature > 37.5°C) or gives a history of fever within the past 24 hours, a 
fingerprick blood sample will be obtained for repeat thick smear, and filter paper sample. 
Haemoglobin will be re-evaluated on day 42. At each follow-up visit, study clinicians 
will assess participants according to a standardized clinical record form, to allow 
objective and complete quantification of adverse events and tolerability (Appendices G 
and H). Participants who are absent from school on the day of a scheduled visit will be 
visited at home and, if necessary, transported to school for evaluation by the study 
physicians.   
  
Table 7. Follow-up Schedule 
 Day 
0 
Day 
1 
Day 
2 
Day 
3 
Day 
7 
Day 
14 
Day 
28 
Day 
42 
Unscheduled 
day 
Study drugs X X X       
History X X X X X X X X X 
Temperature X X X X X X X X X 
Physical exam X X X X X X X X X 
Blood smear X   X X X X X X 
Filter paper sample X   X X X X X X 
Haemoglobin X       X  
Assessment for AEs X X X X X X X X X 
Student questionnaire     X     
X = perform this task       
 
 
7.2 Unscheduled follow-up 
If a participant falls ill on a day which no follow-up assessment is scheduled, they will be 
instructed to inform school staff of their illness (if they are able to attend school). The 
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school staff will be instructed to notify the study team of the participant’s illness so that 
appropriate follow-up can be arranged. Members of the study team will visit participating 
schools every weekday during the study period and will ensure appropriate follow-up of 
any ill participants. If a participant falls ill and is not able to attend school, they will be 
instructed to attend a designated study clinical site (presenting their study identification 
card) for evaluation and treatment. Study team members will also visit all designated 
clinical sites every day (including weekends) to ensure appropriate follow-up of study 
participants. 
 
7.3  Management of malaria 
Rescue therapy with antimalarials will be provided in the following situations (Table 2).  
 
– Development of danger signs or severe malaria on Days 0 to 42 in the presence of 
parasitaemia 
– Development of hyperparasitaemia (> 10,000/ul) on Days 1 to 42 
– Temperature > 37.5C (A), or history of fever in previous 24 hours, on Days 3 to 42 
in the presence of parasitaemia 
– Presence of parasitaemia on Day 42 and axillary temperature  < 37.5C (A), without 
previously meeting any of the criteria of clinical failure 
 
Any participant who meets requirements for rescue therapy during follow-up and is 
diagnosed with uncomplicated malaria will be treated with AL. Any participant, who 
meets requirements for rescue therapy and is diagnosed with severe malaria or danger 
signs will be referred for treatment with quinine. Any participant who meets requirements 
for rescue therapy will continue to be followed for the full 42 days.  
 
7.4 Management of non-malaria illnesses 
Participants who are found to have illnesses other than malaria will receive standard-of-
care treatment from the study physicians, according to standardized algorithms, or will be 
referred appropriately. We will avoid the routine use of medications with antimalarial 
activity, including tetracycline, antifolate, and macrolide antibiotics, when acceptable 
alternatives are available.  
 
7.5 Evaluation of acceptability 
Participants will be interviewed on day 7 using a semi-structured questionnaire to capture 
data on the acceptability of treatment (Appendix J). 
  
7.6 Criteria for exclusion from efficacy analysis 
Participants will be excluded from further study participation in the following situations: 
1. If consent to participate in the study is withdrawn 
2. If a child is lost to follow-up 
 
If any of the following occurs, the participant will continued to be followed for the full 42 
days, but will not have an efficacy outcome assigned: 
1. Use of antimalarial drugs outside of the study protocol 
2. Incomplete treatment with study medications 
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8.0  LABORATORY EVALUATIONS 
 
8.1 Microscopy 
Thick and thin blood smears will be stained with 2% Giemsa for 30 minutes and read by 
experienced laboratory technologists who are not involved in direct participant care. 
Parasite densities will be calculated by counting the number of asexual parasites per 200 
leukocytes (or per 500 leukocytes, if the count is <10 asexual parasites/200 leukocytes), 
assuming a leukocyte count of 8,000/l. A blood smear will be considered negative when 
the examination of 100 high power fields does not reveal asexual parasites. 
Gametocytaemia will also be determined from thick smears. Thin smears will be used for 
parasite species identification. For quality control, all slides will be read by a second 
microscopist and a third reviewer will settle any discrepant readings.     
 
8.2  Haemoglobin measurement 
Haemoglobin will be measured from fingerprick blood samples using a portable 
spectrophotometer (HemoCue, Anglom, Sweden). 
 
8.3 Molecular studies 
Each time a thick blood smear is obtained blood will also be collected onto filter paper. 
Samples will be collected by fingerprick sampling. Blood will be placed onto filter paper 
in approximately 25 ul aliquots per blood spot (4 blood spots per sample). The samples 
will be labeled with study numbers and dates, air-dried, and stored in small, sealed 
sample bags at ambient temperature with desiccant. Parasite DNA will subsequently be 
removed from the filter paper and prepared for molecular analysis using a chelex 
extraction method. Genotyping will be performed on all participants with parasitaemia 
during follow-up, who had parasitaemia on day 0. Genotyping of parasites collected at 
baseline (day 0) and the day of recurrent parasitaemia will be done to distinguish between 
true recrudescence and new infections. Briefly, selected regions of the merozoite surface 
protein-2 gene, merozoite surface protein-1 gene, and 6 microsatellite markers will be 
amplified using PCR and characterized based on sequence and size polymorphisms 
identified by gel electrophoresis.42 Genotyping patterns on the day of recurrent 
parasitaemia will be compared with those at treatment initiation using GelCompar II 
software (Applied Maths). Additional molecular studies may include analyses of 
polymorphisms in parasite and/or human genes for mutations that may impact on clinical 
malaria. Molecular studies will be performed only for research purposes and will have no 
impact on the clinical management of study participants.  
 
8.4 High performance liquid chromatography (HPLC) 
Blood samples collected on day 0, and on any other day that a participant is suspected to 
have taken an antimalarial outside of the study protocol, will be screened to detect the 
presence of antimalarial drugs or their metabolites by HPLC methods developed at 
LSHTM (Harparkash Kaur, personal communication). 
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9.0 ADVERSE EVENT MONITORING 
 
9.1 Definitions 
An adverse event (AE) is defined as "any untoward medical occurrence in a participant or 
clinical investigation participant administered a pharmaceutical product that does not 
necessarily have a causal relationship with this treatment" (ICH Guidelines E2A).  An 
adverse event can further be broadly defined as any untoward deviation from baseline 
health which includes (International Centers for Tropical Disease Research Network 
Investigator Manual, Monitoring and Reporting Adverse Events, 2003):  
 Worsening of conditions present at the onset of the study 
 Deterioration due to the primary disease 
 Intercurrent illness 
 Events related or possibly related to concomitant medications  
 
A serious adverse event (SAE) is defined as an experience that results in any of the 
following outcomes:  
 Death during the period of study follow-up 
 Life-threatening experience (one that puts a participant at immediate risk of death at 
the time of the event)  
 Inpatient hospitalization during the period of study follow-up 
 Persistent or significant disability or incapacity 
 Specific medical or surgical intervention to prevent one of the other serious outcomes 
listed in the definition. 
 
9.2 Identification of adverse events  
At each follow-up visit (days 1, 2, 3, 7, 14, 28, 42, and any unscheduled day), study 
clinicians will assess participants according to a standardized clinical record form 
(Appendix G). A severity grading scale, based on toxicity grading scales developed by 
the WHO and the National Institutes of Health, Division of Microbiology and Infectious 
Diseases, will be used to grade severity of all symptoms, physical exam findings, and 
haemoglobin results (Appendix H). Any new event, or an event present at baseline that is 
increasing in severity, will be considered an adverse event.  
 
9.3  Reporting of adverse events 
For each possible adverse event identified and graded as moderate, severe or life 
threatening, an adverse event report form will be completed (Appendix K).  The 
following information will be recorded for all adverse experiences that are reported:  
 Description of event  
 Date of event onset 
 Date event reported 
 Maximum severity of the event 
 Maximum suspected relationship of the event to study medication  
 Is the event serious? 
 Initials of the person reporting the event 
 Was the event episodic or intermittent in nature? 
 Outcome  
 IPT in schoolchildren, Version 1.3, 17 March 2008 
 
22 
 Date event resolved 
 
9.4 Reporting of serious adverse events 
Guidelines for reporting of serious adverse events provided by the Makerere University 
Research and Ethics Committee, the Ugandan National Council for Science and 
Technology, the London School of Hygiene & Tropical Medicine, and the data and safety 
monitoring board (DSMB) will be followed. 
 
10.0 STATISTICAL ISSUES 
 
10.1 Sample size calculations 
Sample size calculations are based on the primary endpoint to compare the risk of 
parasitaemia after 42-days follow-up in each of the different combination antimalarial 
regimens, including AQ+SP and DP, and placebo, to SP. The following sample sizes 
have been calculated for children treated with SP and assume that 50% of children will 
have a negative blood slide at enrollment, while 50% will be positive.  Of those with a 
negative smear, 50% are assumed to have a positive blood smear during 42-day follow-
up, while 80% of those with a positive smear at enrollment are assumed to have a 
positive blood smear during follow-up.  Hence, the assumed risk of parasitaemia after 42 
days of follow-up among those receiving SP is 65%. No formal adjustments for multiple 
comparisons of treatment arms have been made. 
 
10.1.1 Initial sample size calculations based on superiority. Initial sample size 
calculations were based on providing a 95% probability of detecting a treatment effect 
when the true difference in the risk of parasitaemia is ≥15%.  This value is based on 
previous studies of efficacy of the different regimens. The null hypothesis is that the true 
difference in the risk of parasitaemia at 42 days follow up between each of the treatment 
regimens and SP is zero versus an alternative is that there is a difference.  Assuming 80% 
power and 10% losses to follow-up a total of 760 children (190 per arm) are required.43 
 
10.1.2  Secondary sample size calculations based on non-inferiority. Once the initial 
target sample size is reached, an interim report will be prepared for the data and safety 
monitoring board (DSMB, section 11.0). If no significant difference in efficacy is 
detected between SP and the alternative regimens, and a decision is made to continue the 
study based on results on the interim analysis, recruitment will continue until the 
secondary sample size is reached.  Secondary sample size calculations are based on 
assessing non-inferiority by a one-sided 97.5% confidence interval for the difference in 
risk of parasitema after 42 days between SP and each of the antimalarial regimens and 
placebo.  The null hypothesis is that SP is inferior to the treatment regimens by more than 
10% versus an alternative hypothesis that it is not. The 10% difference in risks is smaller 
than that assumed for superiority.  The value of 10% was chosen since this is the largest 
increase in risk that can be judged as clinically acceptable and was chosen based on 
clinical relevance and previous studies of treatment efficacy.  Assuming 80% power and 
10% losses to follow-up a total of 1600 children (400 per arm) are required i.e. an 
additional 840 children.44 
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10.2 Analytical plan 
10.2.1 Overview. This section briefly describes the statistical methods to be used; a 
detailed analytical plan will be independently reviewed by the data and safety monitoring 
board (section 11.0). Data analysis will be primarily performed by the project 
epidemiologist and the study statistician. Descriptive statistics will be used to summarize 
baseline characteristics of study participants. Efficacy and safety data will be evaluated 
using a modified intention-to-treat analysis and will only include participants who meet 
all selection criteria. Because final selection criteria are assessed on Day 1 after final 
reading of the enrollment thick and thin smears, some participants randomized to 
treatment but not fulfilling selection criteria will be excluded from the modified 
intention-to-treat analysis. Estimates will be presented with their 95% confidence 
intervals. For all efficacy outcomes, “survival” curves (i.e. has not experienced outcome 
of interest by time t) will be examined using Kaplan-Meier and formally compared 
between treatment regimens. Participants excluded after enrollment will be censored at 
the time of their last assessment.  No formal adjustments for multiple comparisons will be 
made. Statistical tests will use a two-sided significance level of 5%.   
 
10.2.2 Primary outcome: risk of parasitaemia. Risk of parasitaemia after 42 days of 
follow-up will be estimated for each treatment regimen using results unadjusted by 
genotyping, and risk differences calculated. Corresponding 95% confidence intervals and 
hypothesis testing will be carried out for risk difference.  Time to first episode of 
parasitaemia and time to symptomatic parasitaemia (including parasitaemia associated 
with evidence of danger signs or severe malaria, fever, or history of fever in previous 24 
hours) will be estimated. The analysis will also be stratified by presence vs. absence of 
parasites and age at enrollment. 
 
10.2.3 Secondary outcomes: risks of recrudescence, new infection, clinical failure, 
and parasitological failure. Risk of recrudescence and risk of new infection will be 
estimated using results adjusted by genotyping, and risk differences calculated. 
Corresponding 95% confidence intervals and hypothesis testing will be carried out for 
risk difference. Time to first episode of parasitaemia and time to symptomatic 
parasitaemia will be estimated.  For risk of recrudescence using genotyping adjusted 
outcomes, participants with recurrent parasitaemia due to new infections will be 
censored. Risks of clinical failure and parasitological failure due to recrudescence 
(adjusted by genotyping) in participants who are parasitaemic at enrollment will also be 
estimated as time to event. These analyses will also be stratified by age at enrollment. 
 
10.2.4 Secondary outcomes: safety, tolerability, and acceptability. The risk of 
adverse events after 14 and 42 days of follow-up and the risk of serious adverse events in 
the treatment groups (SP, AQ+SP, and DP) will be compared to that in the placebo 
group. The analysis will also be stratified by presence vs. absence of parasites at 
enrollment. To evaluate acceptability, a questionnaire will be administered to participants 
on day 7. The acceptability of the different treatment groups will be compared to that of 
placebo. Categorical variables will be compared between the treatment groups using chi-
square tests or Fisher’s exact tests and continuous variables will be compared using t-
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tests or non-parametric tests where appropriate.  No formal adjustments for multiple 
comparisons will be made. Statistical tests will use a two-sided significance level of 5%.   
 
 
11.0 DATA AND SAFETY MONITORING BOARD 
 
11.1 Data and safety monitoring board 
A data and safety monitoring board will be assembled in conjunction with the LSHTM, 
consisting at a minimum of a chairman, a safety monitors, a clinical monitor, and a 
statistician.    
 
11.2 Monitoring plan 
An interim report will be prepared for review by the DSMB when the initial target 
sample size is reached. A shell report for the interim report will be prepared and 
presented to the DSMB for approval prior to the interim review. For the interim review, 
the study statistician will prepare a blinded summary (containing information on study 
progress and data quality, including participant recruitment, participant follow-up, and 
protocol adherence). Efficacy data and safety data on serious adverse events will be 
reported by anonymised drug groups. Only the members of the DSMB will have access 
to the drug codes and will be able to unblind the data in the interim report. In addition, 
the clinical monitor will be asked to review any serious adverse events identified during 
the study.  The clinical monitor will prepare a report including an assessment of the 
causality of the events and the report will be presented to the other members of the 
DSMB for review. 
 
11.3 Stopping guidelines 
Interpretation of results and decisions about discontinuation of the study will be made by 
the members of the DSMB. Stopping guidelines will be outlined in detail in the DSMB 
shell report, and will be based on the primary outcome (risk of parasitaemia, unadjusted 
by genotyping, after 42 days of follow-up comparing the alternative regimens, including 
AQ+SP and DP, to SP), and the incidence of serious adverse events (for all treatment 
groups as compared to placebo). 
 
 
12.0 DATA COLLECTION AND MANAGEMENT 
 
12.1 Data management  
All clinical data will be recorded onto standardised case record forms by study clinicians. 
Laboratory data will be recorded in a laboratory record book by the study laboratory 
technicians and then transferred to the case record forms by the study clinicians.  Data 
will be transferred from the case record forms into a computerised database (EPI INFO 
6.04) by data entry personnel and will be double entered to verify accuracy of entry.   
Two back-up files of the database will be stored on compact discs after each data entry 
session.   For quality control, check programs will be written into the database to limit the 
entry of incorrect data and ensure entry of data into required fields. 
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12.2 Data quality assurance and monitoring   
All members of the study team will be educated in the study protocol prior to the onset of 
the trial.   The study clinicians will complete case record forms at each participant visit.  
These forms will be reviewed by the study coordinator for completeness and accuracy.  
For quality control of thick blood smear slide readings, expert microscopists who will be 
blinded to the participant’s treatment group will repeat the reading of all slides. All 
discrepant slide readings will be resolved based on the results of a 3rd reading. Study 
group meetings will be conducted by the coordinator to assess progress of the study, 
address any difficulties, and provide performance feedback to the members of the study 
group. In addition members from the core facility will make regular visits to active study 
sites as needed.   
 
12.3 Records   
Case record forms will be provided for each participant.  Participants will be identified by 
their initials and study identification number on the case record form. Participant names 
will not be entered into the computerised database. All participant record forms will be 
kept in individual files in a secure filing cabinet in the study clinic.  All corrections will 
be made on case record forms by striking through the incorrect entry with a single line 
and entering the correct information adjacent to it.  The correction will be initialed and 
dated by the investigator.  Additional records will be kept in the clinical and laboratory 
record books at the core facility in Kampala. The investigators will allow all requested 
monitoring visits, audits or reviews. 
 
 
13.0 PROTECTION OF HUMAN PARTICIPANTS 
 
13.1 Institutional Review Board (IRB) review  
This protocol and the informed consent documents, including any additional educational 
or recruitment material, will be reviewed and approved by all IRBs before the trial 
begins. Any amendments or modifications to this material will also be reviewed and 
approved by the IRBs prior to implementation. The IRBs will include: 
 
London School of Hygiene & Tropical Medicine (LSHTM) Ethics Committee 
Address: Keppel Street, London, WC1E 7HT, UK 
Contact Person:  Gemma Howe 
Phone Number:  +44 (0) 20 7927 2802 
Email: Ethics@lshtm.ac.uk       
 
Makerere University, Research and Ethics Committee (MUREC) 
Address: Makerere University, Faculty of Medicine, Office of the Dean, PO Box 
7072, Kampala, Uganda 
Contact Person:  Dr. Charles Ibingira 
Phone Number:  +256 (0) 414-530020 
Fax Number:      +256 (0) 414-531091 
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Uganda National Council of Science and Technology (UNCST) 
Address: Uganda House, 11th Floor, PO Box 6884, Kampala, Uganda 
Contact Person:  Dr. Thomas Gordon Egwang 
Phone Number:  +256 (0) 414-250499 
Fax Number:      +256 (0) 414-234579 
 
13.2 Informed consent process 
Meetings will be held with the parents/guardians of children enrolled in standards 3-7 to 
describe the purpose of the study, the procedures to be followed, and the risks and 
benefits of participation.   Information sheets and consent forms will be provided to the 
parents or guardians for their review.  The parents or guardians will be asked to sign 
consent for their child to participate in the research study.  If a parent or guardian is 
unable to read or write, his/her fingerprint will be used in substitute for a signature, and a 
signature from a witness to the informed consent discussion will be obtained.  Parents or 
guardians will be informed that participation of their child(ren) in the study is completely 
voluntary and that they may withdraw from the study at any time. Written assent to 
participate in the study will also be obtained from the student at the time of screening.  
 
13.3  Risks and discomforts 
13.3.1 Privacy. Care will be taken to protect the privacy of participants, as described in 
this protocol. However, there is a risk that others may inadvertently see participants’ 
medical information, and thus their privacy compromised.  
 
13.3.2 Risks of randomization. This will be a randomized trial, and some treatment 
arms may prove to be more or less efficacious, more or less well tolerated, and/or more or 
less safe than others. Thus, there is the risk that participants will be randomized to less 
efficacious, less well tolerated, and/or less safe treatment regimens. Interim analysis is 
planned to limit the number of participants exposed to any regimen that proves to be less 
efficacious or less safe. Some children will be randomized to receive placebo, however, 
the risk of receiving placebo in this study is minimal. This study is designed to evaluate 
asymptomatic children who generally would not be tested or treated for malaria.  
Children who are febrile or have a history of fever, or who have evidence of severe 
malaria or danger signs will be excluded from the study, treated appropriately, and 
referred if necessary. Children with a parasite density > 10,000/ul at enrollment will be 
also excluded and treated with AL or quinine as appropriate, in accordance with national 
guidelines. Children enrolled in the study will be closely monitored during the 42 days of 
follow-up and any child who develops clinical malaria will be treated with AL or quinine 
as appropriate.  In addition, all children who are parasitaemic on day 42 will be treated, 
regardless of clinical symptoms.      
 
13.3.3 Fingerprick blood draws. Risks include pain, transient bleeding and soft-tissue 
infection. 
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13.3.4 Risk of sulfadoxine-pyrimethamine (SP) 
SP has generally been the preferred replacement for CQ for the treatment of 
uncomplicated malaria in Africa. Although technically a combination regimen, SP is 
generally considered a single antimalarial agent, as its success depends on the synergistic 
action of its two component inhibitors of folate synthesis. SP is approved in the USA for 
the treatment of falciparum malaria and for chemoprophylaxis against malaria in 
travelers, but it is no longer recommended for this second use due to rare, but serious 
toxicity. Adverse reactions listed on the SP package insert (Roche, USA) are blood 
dyscrasias (agranulocytosis, aplastic anaemia, thrombocytopenia), allergic reactions 
(erythema multiforme and other dermatological conditions), gastrointestinal reactions 
(glossitis, stomatitis, nausea, emesis, abdominal pain, hepatitis, diarrhea), central nervous 
system reactions (headache, peripheral neuritis, convulsions, ataxia, hallucinations), 
respiratory reactions (pulmonary infiltrates), and miscellaneous reactions (fever, chills, 
nephrosis); based on widespread experience with the drug, all of these reactions appear to 
be uncommon or rare with short-term therapeutic use. The best-documented severe 
adverse effects with SP are cutaneous reactions, primarily noted when SP was used for 
long-term chemoprophylaxis in non-African populations. Reported rates of serious 
reactions to SP in the UK, with long-term use for chemoprophylaxis, were 1:2100, with 
1:4900 serious dermatological reactions and 1:11,100 deaths.45 Estimated rates of toxicity 
in the US were 1:5000-8000 severe cutaneous reactions and 1:11,000-25,000 deaths.46 
Clinical experience suggests that risks of severe toxicity are much lower with malaria 
treatment regimens in Africa. Overall, the risk of severe reactions occurring in 
developing countries with single-dose SP treatment has been estimated at 0.1 per 
million.47 
 
13.3.5 Risk of amodiaquine (AQ) 
AQ has been described as “very well tolerated” for routine use,48 and it was widely used 
for chemoprophylaxis against malaria in travelers (with weekly treatment) in the past. 
However, prophylactic use was discontinued due to rare instances of agranulocytosis, 
aplastic anaemia, and hepatotoxicity, principally associated with use for malarial 
chemoprophylaxis in travelers.48,49 Side effects listed as occasional on the package insert 
(Pfizer/Parke-Davis, Senegal) are nausea, vomiting, diarrhea, lethargy, agranulocytosis 
and other blood dyscrasias, hepatitis, and peripheral neuropathy. Reported rates of serious 
reactions to AQ in the UK were 1:2100 blood dyscrasias, 1:31,000 deaths from blood 
dyscrasias, and 1:15,650 serious hepatotoxicity.45 Toxicities with short-term use for 
treatment are expected to be much lower, although data are limited.49-53 In a review of 40 
published and unpublished clinical trials, no severe or life-threatening adverse event was 
noted.49 Considering tolerability in 488 AQ-treated patients, gastrointestinal toxicities 
and pruritis were most commonly reported, and the incidence of adverse events was 
similar among patients treated with AQ, CQ, and SP.49 At our study site in Uganda, no 
serious toxicities were observed with AQ monotherapy (131 treatments).52  
 
13.3.6 Risk of artemisinins 
Artemisinin derivatives have now been extensively studied, and they are remarkable for a 
lack of serious toxicity when used for the treatment of malaria.54 Considering all 
artemisinins, 15% (12,463) of the patients enrolled in all published antimalarial drug 
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trials over the past 50 years have received an artemisinin compound, and there are more 
trials on these compounds than on any other antimalarials (N. White, unpublished 
communication). In addition to formal studies, artemisinins have now been widely used, 
with well over a million treatments, mostly of artesunate (AS), in Southeast Asia. The 
only serious toxicity which has emerged in detailed prospective clinical evaluations is a 
low risk of type 1 hypersensitivity reactions (estimated risk 1:2833, 95% CI 1:1362-
1:6944).55 Electrocardiograms and detailed neurological, audiometric, and 
neurophysiological tests have failed to show any evidence for cardiac or neurological 
toxicity in humans (see below for more details).56,57 
 
Animal studies have led to some concerns over artemisinins, particularly regarding 
cardiac and neurological effects, and reproductive toxicity. As slight QT prolongation 
was observed in dogs treated with high doses, detailed electrocardiographic studies have 
been conducted in humans during treatment for falciparum malaria.57-59 Taking into 
account effects of malaria, no significant effects of artemisinins on the QT interval were 
identified.   
 
The neurological effects of artemisinins have been very extensively studied. In mice, rats, 
dogs, and monkeys, high dosages of intramuscular artemether and arteether produce an 
unusual and selective pattern of damage to certain brainstem nuclei, particularly those of 
the auditory and vestibular systems.60-68AS is transformed in vivo to dihydroartemisinin, 
which is the most neurotoxic of the artemisinin derivatives.69,70 However, in the animal 
models, orally administered AS and dihydroartemisinin are considerably less neurotoxic 
than intramuscular artemether or arteether. Differences in toxicity are explained by 
differences in pharmacokinetics of different compounds and different routes of 
administration.65,67,68,71  Neurotoxicity results from the long-lasting blood concentrations 
that follow intramuscular injection of the oil-soluble compounds, artemether and 
arteether. Oral administration of artemether or arteether, which provides much more rapid 
absorption and elimination than intramuscular dosing, leads to markedly less 
neurotoxicity in mice, although oral artemether can be made more neurotoxic by giving 
the drug in small repeated doses to simulate the constant exposure that follows 
intramuscular injection.65 Artesunate is much less toxic than arteether in rats when 
administered intramuscularly 62or orally.66,67,69 Importantly, with high dose intramuscular 
injections of artemether and arteether, clinical assessment of mice was a sensitive 
indicator of neurotoxicity; no mice with normal clinical exams showed histopathology.69 
   
The artemisinin derivatives are remarkably well tolerated in humans. In a clinical safety 
review of 108 studies including 9,241 patients, no serious adverse events or significant 
toxicity was reported.72 In addition, a systematic review of artemisinin derivatives for 
treating uncomplicated malaria, including 41 studies of 5,240 patients, showed no 
evidence of harmful effects related to artemisinin derivatives.32 Clinical studies have 
shown no convincing evidence for neurotoxicity after treatment with artemisinin 
derivatives, though neurological effects of acute malaria are common. One letter 
described ataxia and slurred speech after AS therapy, but these findings were consistent 
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with the course of severe malaria.73 To specifically evaluate for potential artemisinin-
associated auditory toxicity in humans, van Vugt et al. performed clinical neurological 
evaluations, audiometry and early latency auditory evoked responses in 79 patients 
treated with multiple doses of artemether or artesunate and 79 matched controls in 
Thailand, and no evidence of auditory toxicity was detected.57 Comparisons of patients 
who had received multiple courses of artemisinin derivatives with age-matched untreated 
controls showed no significant differences in clinical, audiometric, or auditory evoked 
potential measurements.56,57 Even considering the most worrisome dosing regimen, there 
is no evidence that clinical use of intramuscular artemether has caused neurotoxicity. In a 
new report, four independent neuropathologists examined the brains of patients who died 
after treatment with intramuscular artemether, and there was no evidence for the 
characteristic pattern of neuropathological change seen in the animal studies.(Ref Hien 
2003) These results suggest a wide margin of safety for artemisinins in clinical use, 
particularly when given orally, particularly for water soluble compounds, and most 
particularly for the most widely studied water-soluble agent, AS.       
 
13.3.7 Risk of dihydroartemisinin-piperaquine (DP). DP is an artemisinin-containing 
fixed-combination drug developed in China. Recent randomized clinical trials in 
Cambodia, Vietnam, and Thailand indicate excellent tolerability and high cure rates 
against multi-drug resistant falciparum malaria. Artemisinin derivatives such as 
dihydroartemisinin have been used safely in large numbers of participants with 
uncomplicated or severe malaria. Piperaquine has been used less widely. In a study of the 
safety and efficacy of DP in 106 Cambodian children and adults with uncomplicated 
malaria, adverse events were uncommon (< 5%), mild, short lived, and difficult to 
distinguish from symptoms of malaria (anorexia, nausea, vomiting, abdominal pain, 
diarrhea, and dizziness).74 In a safety evaluation of DP in 62 Cambodian children and 
adults with malaria, DP was found to be safe and well tolerated with no evidence of 
clinically significant postural hypotension, QTc prolongation, or propensity for 
hypoglycemia.75 In a clinical trial of DP in 166 Vietnamese participants with 
uncomplicated malaria, 3% of participants reported minor adverse events, mostly 
transient nausea, which were self limited and resolved with the abatement of fever.76 In a 
dose-optimization clinical trial of DP in 487 children and adults from Thailand with 
uncomplicated malaria, DP was well tolerated, with a low incidence of mild adverse 
events, which were mainly upper gastrointestinal and were similar to those reported in 
other studies.77 In a clinical trial of DP in 331 children and adults from Thailand with 
uncomplicated malaria, DP was well tolerated, with a low incidence of mild side effects 
and now serious adverse events felt to be likely related to the study drug.78 DP is now in 
routine use in Vietnam with no reports of serious adverse events (although with the 
acknowledgment that there are limited resources available there for pharmacovigilance).  
 
13.4 Compensation  
All antimalarial medication, and the evaluation and treatment for some routine medical 
problems encountered during follow-up will be provided free of charge.  If cases are 
referred by study staff to a health facility for further assessment, transportation will either 
be provided by the study team, or the costs of transportation will be borne by the project. 
Medical care that the participant receives which is unrelated to malaria will remain the 
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primary responsibility of the participant, parent or guardian, although routine medical 
problems will generally be managed by the study at no cost to the participant. 
 
13.5  Alternatives  
Individuals whose parents or guardians choose not to participate in this study will not be 
enrolled. Children excluded from the study will still be eligible for standard care of 
medical problems as they arise at the government health dispensaries or other medical 
facilities in the UMSP sentinel sites. 
 
13.6   Confidentiality of records  
Participants, parents and guardians will be informed that participation in a research study 
may involve a loss of privacy. All records will be kept as confidential as possible. 
Participants will be identified primarily by their study number and participant names will 
not be entered into the computerized database. No individual identities will be used in 
any reports or publications resulting from the study.  
 
 
14.0 STUDY TEAM AND PARTICIPATING SITES 
 
14.1 Investigators and collaborators 
 
Sarah Staedke 
Role in project: Principal investigator 
Clinical Senior Lecturer, London School of Hygiene and Tropical Medicine  
Co-investigator, Uganda Malaria Surveillance Project 
 
Sian Clarke 
Role in project: Co-investigator 
Senior Lecturer, London School of Hygiene and Tropical Medicine  
 
Simon Brooker 
Role in project: Co-investigator 
Reader, London School of Hygiene and Tropical Medicine  
Research Fellow, KEMRI/Wellcome Trust Collaborative Programme, Nairobi, Kenya 
 
Ambrose Talisuna 
Role in project: Co-investigator 
Co-investigator, Uganda Malaria Surveillance Project 
 
Richard Ndyomugyenyi  
Role in project: Co-investigator 
Vector Control Division, Ministry of Health 
 
Narcis Kabatereine 
Role in project: Collaborator 
Vector Control Division, Ministry of Health 
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Benson Estambale 
Role in project: Collaborator 
University of Nairobi Institute for Infectious and Tropical Diseases, Kenya 
 
 
Bonnie McGlone 
Role in project: Study statistician 
Research fellow, London School of Hygiene and Tropical Medicine 
 
Harparkash Kaur 
Role in project: Collaborator 
London School of Hygiene and Tropical Medicine  
 
Daniel Chandramohan 
Role in project: Collaborator 
London School of Hygiene and Tropical Medicine  
 
 
14.2 Participating sites 
 
Uganda Malaria Surveillance Project (UMSP) 
 Address: Uganda Malaria Surveillance Project, P.O. Box 7475, Kampala, Uganda 
 Contact Person: Catherine Tugaineyo 
 Phone Number: +256 (0) 414-530692 
 Fax Number:     +256 (0) 414-540524 
 Email: ctugaineyo@yahoo.com 
 
London School of Hygiene & Tropical Medicine (LSHTM) 
Address: Keppel Street, London, WC1E 7HT, UK 
Contact Person:  Susan Sheedy 
Phone Number: +44(0) 20 7927 2256  
Fax Number:     +44(0)20 7637 4314 
Email: susan.sheedy@lshtm.ac.uk 
 
Vector Control Division, Ugandan Ministry of Health 
Address: VCD, Ministry of Health, PO Box 1661 
Contact Person: Dr. Narcis Kabatereine 
Phone Number: +256 (0) 772-492078 
Email: vcd_sci@utlonline.co.ug 
 
 
15.0 FUNDING AGENCY 
 
Gates Malaria Partnership 
Address: 50 Bedford Square, London, WC1B 3DP, UK 
Contact Person:  Dr. Amit Bhasin 
 IPT in schoolchildren, Version 1.3, 17 March 2008 
 
32 
Phone Number:  +44 (0) 207 299 4711  
Email: amit.bhasin@lshtm.ac.uk 
       
 
16.0 CAPACITY BUILDING 
 
The research builds upon existing collaborations between LSHTM and the University of 
Nairobi and the Division of Malaria Control (DOMC) in Kenya, and between LSHTM 
and the Vector Control Division (VCD) in Uganda. The structure of existing (solid lines) 
and proposed (dashed lines) collaborations is presented in the schematic below.  
 
 
LSHTM
UMSPVCD
University of 
Nairobi
MU-UCSF
Division of 
Malaria Control
 
 
The proposed collaboration with the Uganda Malaria Surveillance Project (UMSP) brings 
an important scientific dimension to this work, notably expertise in conducting drug 
efficacy trials. UMSP links academic researchers from the Makerere University - 
University of California, San Francisco (MU-UCSF) Research Collaboration with the 
Uganda Ministry of Health, and undertakes malaria research in sentinel sites around 
Uganda. Current research activities conducted by UMSP and MU-UCSF include 
antimalarial treatment efficacy studies in contrasting transmission settings, malaria 
surveillance, pharmacovigilance, and assessment of home-based management of fever, 
HIV and malaria co-infection, and the utility of rapid diagnostic tests for malaria. Future 
research directions for UMSP include expansion of surveillance and epidemiological 
capacity.  
 
This study will contribute to capacity building by strengthening links between the various 
research organizations, and through training. Staff from VCD in Uganda and from 
DOMC in Kenya will receive hands-on training in malaria laboratory methods, including 
an intensive training course in laboratory procedures, developed as part of the ongoing 
Joint Uganda Malaria Training Programme (JUMP) coordinated by Infectious Diseases 
Institute and UMSP. In turn, UMSP will gain greater experience in the conduct of 
community-based clinical trials through collaboration with VCD in Uganda. Hands-on 
epidemiological training will be provided to UMSP staff by the LSHTM PIs. At least as 
importantly, the project will help strengthen regional collaboration and skill sharing, and 
help form the basis for future, regional collaborative research.  
 
 
 IPT in schoolchildren, Version 1.3, 17 March 2008 
 
33 
 
17.0 REFERENCES 
 
1. Breman JG, Alilio MS, Mills A. Conquering the intolerable burden of malaria: what's 
new, what's needed: a summary. Am J Trop Med Hyg 2004;71(2 Suppl):1-15. 
2. Breman J. The ears of the hippopotamus: manifestations, determinants, and estimates 
of the malaria burden. Am J Trop Med Hyg 2001;64:1-11. 
3. Snow RW, Craig M, Deichmann U, Marsh K. Estimating mortality, morbidity and 
disability due to malaria among Africa's non-pregnant population [see comments]. 
Bull World Health Organ 1999;77(8):624-40. 
4. Greenwood BM. The epidemiology of malaria. Ann Trop Med Parasitol 
1997;91(7):763-9. 
5. Marsh K, Forster D, Waruiru C, Mwangi I, Winstanley M, Marsh V, Newton C, 
Winstanley P, Warn P, Peshu N, et al. Indicators of life-threatening malaria in 
African children. N Engl J Med 1995;332(21):1399-404. 
6. Murphy SC, Breman JG. Gaps in the childhood malaria burden in Africa: cerebral 
malaria, neurological sequelae, anemia, respiratory distress, hypoglycemia, and 
complications of pregnancy. Am J Trop Med Hyg 2001;64(1-2 Suppl):57-67. 
7. Snow RW, Trape JF, Marsh K. The past, present and future of childhood malaria 
mortality in Africa. Trends Parasitol 2001;17(12):593-7. 
8. Marsh K, Snow RW. Host-parasite interaction and morbidity in malaria endemic areas. 
Philos Trans R Soc Lond B Biol Sci 1997;352(1359):1385-94. 
9. Lalloo DG, Olukoya P, Olliaro P. Malaria in adolescence: burden of disease, 
consequences, and opportunities for intervention. Lancet Infect Dis 
2006;6(12):780-93. 
10. Black RE, Morris SS, Bryce J. Where and why are 10 million children dying every 
year? Lancet 2003;361(9376):2226-34. 
11. World Health Organization. A strategic framework for malaria prevention and control 
during pregnancy in the African region. 2004(AFR/MAL/04/01). 
12. Schultz LJ, Steketee RW, Macheso A, Kazembe P, Chitsulo L, Wirima JJ. The 
efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or 
chloroquine in preventing peripheral and placental Plasmodium falciparum 
infection among pregnant women in Malawi. Am J Trop Med Hyg 
1994;51(5):515-22. 
13. Verhoeff FH, Brabin BJ, Chimsuku L, Kazembe P, Russell WB, Broadhead RL. An 
evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in 
pregnancy on parasite clearance and risk of low birthweight in rural Malawi. Ann 
Trop Med Parasitol 1998;92(2):141-50. 
14. Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, Misore A, Muga R, Oloo 
AJ, Steketee RW. Efficacy of sulfadoxine-pyrimethamine for prevention of 
placental malaria in an area of Kenya with a high prevalence of malaria and 
human immunodeficiency virus infection. Am J Trop Med Hyg 1998;59(5):813-
22. 
15. Shulman CE, Dorman EK, Cutts F, Kawuondo K, Bulmer JN, Peshu N, Marsh K. 
Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to 
 IPT in schoolchildren, Version 1.3, 17 March 2008 
 
34 
malaria in pregnancy: a randomised placebo-controlled trial. Lancet 
1999;353(9153):632-6. 
16. Rogerson SJ, Chaluluka E, Kanjala M, Mkundika P, Mhango C, Molyneux ME. 
Intermittent sulfadoxine-pyrimethamine in pregnancy: effectiveness against 
malaria morbidity in Blantyre, Malawi, in 1997-99. Trans R Soc Trop Med Hyg 
2000;94(5):549-53. 
17. Njagi JK, Magnussen P, Estambale B, Ouma J, Mugo B. Prevention of anaemia in 
pregnancy using insecticide-treated bednets and sulfadoxine-pyrimethamine in a 
highly malarious area of Kenya: a randomized controlled trial. Trans R Soc Trop 
Med Hyg 2003;97(3):277-82. 
18. van Eijk AM, Ayisi JG, ter Kuile FO, Slutsker L, Otieno JA, Misore AO, Odondi JO, 
Rosen DH, Kager PA, Steketee RW, Nahlen BL. Implementation of intermittent 
preventive treatment with sulphadoxine-pyrimethamine for control of malaria in 
pregnancy in Kisumu, western Kenya. Trop Med Int Health 2004;9(5):630-7. 
19. Guyatt HL, Noor AM, Ochola SA, Snow RW. Use of intermittent presumptive 
treatment and insecticide treated bed nets by pregnant women in four Kenyan 
districts. Trop Med Int Health 2004;9(2):255-61. 
20. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M, Mshinda H, 
Alonso P. Intermittent treatment for malaria and anaemia control at time of 
routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. 
Lancet 2001;357(9267):1471-7. 
21. Desai MR, Mei JV, Kariuki SK, Wannemuehler KA, Phillips-Howard PA, Nahlen 
BL, Kager PA, Vulule JM, ter Kuile FO. Randomized, controlled trial of daily 
iron supplementation and intermittent sulfadoxine-pyrimethamine for the 
treatment of mild childhood anemia in western Kenya. J Infect Dis 
2003;187(4):658-66. 
22. Massaga JJ, Kitua AY, Lemnge MM, Akida JA, Malle LN, Ronn AM, Theander TG, 
Bygbjerg IC. Effect of intermittent treatment with amodiaquine on anaemia and 
malarial fevers in infants in Tanzania: a randomised placebo-controlled trial. 
Lancet 2003;361(9372):1853-60. 
23. Cisse B, Sokhna C, Boulanger D, Milet J, Ba el H, Richardson K, Hallett R, 
Sutherland C, Simondon K, Simondon F, Alexander N, Gaye O, Targett G, Lines 
J, Greenwood B, Trape JF. Seasonal intermittent preventive treatment with 
artesunate and sulfadoxine-pyrimethamine for prevention of malaria in 
Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet 
2006;367(9511):659-67. 
24. Greenwood B. Review: Intermittent preventive treatment--a new approach to the 
prevention of malaria in children in areas with seasonal malaria transmission. 
Trop Med Int Health 2006;11(7):983-91. 
25. White NJ. Intermittent presumptive treatment for malaria. PLoS Med 2005;2(1):e3. 
26. Brooker S, Guyatt H, Omumbo J, Shretta R, Drake L, Ouma J. Situation analysis of 
malaria in school-aged children in Kenya - what can be done? Parasitol Today 
2000;16(5):183-6. 
27. Bundy DA, Lwin S, Osika JS, McLaughlin J, Pannenborg CO. What should schools 
do about malaria? Parasitol Today 2000;16(5):181-2. 
 IPT in schoolchildren, Version 1.3, 17 March 2008 
 
35 
28. Clarke SE, Brooker S, Njagi JK, Njau E, Estambale B, Muchiri E, Magnussen P. 
Malaria morbidity among school children living in two areas of contrasting 
transmission in western Kenya. Am J Trop Med Hyg 2004;71(6):732-8. 
29. World Health Organization. Malaria prevention and control: an important 
responsibility of a health-promoting school. 2006. 
30. Newman RD, Parise ME, Slutsker L, Nahlen B, Steketee RW. Safety, efficacy and 
determinants of effectiveness of antimalarial drugs during pregnancy: 
implications for prevention programmes in Plasmodium falciparum-endemic sub-
Saharan Africa. Trop Med Int Health 2003;8(6):488-506. 
31. White N. Antimalarial drug resistance and combination chemotherapy. Philos Trans 
R Soc Lond B Biol Sci 1999;354(1384):739-49. 
32. McIntosh HM. Chloroquine or amodiaquine combined with sulfadoxine-
pyrimethamine for treating uncomplicated malaria. Cochrane Database Syst Rev 
2000;2. 
33. Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, Rwakimari JB, 
Rosenthal PJ, Wabwire-Mangen F, Dorsey G, Staedke SG. Artemisinin 
combination therapies for treatment of uncomplicated malaria in Uganda. PLoS 
Clin Trials 2006;1(1):e7. 
34. Okello PE, W VANB, Byaruhanga AM, Correwyn A, Roelants P, Talisuna A, 
D'Alessandro U, Coosemans M. Variation in malaria transmission intensity in 
seven sites throughout Uganda. Am J Trop Med Hyg 2006;75(2):219-25. 
35. Yeka A, Banek K, Bakyaita N, Staedke SG, Kamya MR, Talisuna A, Kironde F, 
Nsobya SL, Kilian A, Slater M, Reingold A, Rosenthal PJ, Wabwire-Mangen F, 
Dorsey G. Artemisinin versus nonartemisinin combination therapy for 
uncomplicated malaria: randomized clinical trials from four sites in Uganda. 
PLoS Med 2005;2(7):e190. 
36. Dorsey G, Njama D, Kamya MR, Cattamanchi A, Kyabayinze D, Staedke SG, 
Gasasira A, Rosenthal PJ. Sulfadoxine/pyrimethamine alone or with amodiaquine 
or artesunate for treatment of uncomplicated malaria: a longitudinal randomised 
trial. Lancet 2002;360(9350):2031-8. 
37. Fanello CI, Karema C, van Doren W, Rwagacondo CE, D'Alessandro U. Tolerability 
of amodiaquine and sulphadoxine-pyrimethamine, alone or in combination for the 
treatment of uncomplicated Plasmodium falciparum malaria in Rwandan adults. 
Trop Med Int Health 2006;11(5):589-96. 
38. Karema C, Fanello CI, Van Overmeir C, Van Geertruyden JP, van Doren W, Ngamije 
D, D'Alessandro U. Safety and efficacy of dihydroartemisinin/piperaquine 
(Artekin((R))) for the treatment of uncomplicated Plasmodium falciparum malaria 
in Rwandan children. Trans R Soc Trop Med Hyg 2006;100(12):1105-11. 
39. World Health Organization. The Abuja declaration and the plan of action. Geneva, 
2003. 
40. Egan A, Crawley J, Schellenberg D. Intermittent preventive treatment for malaria 
control in infants: moving towards evidence-based policy and public health 
action. Trop Med Int Health 2005;10(9):815-7. 
41. World Health Organization. Guidelines for the treatment of malaria. 
2006;WHO/HTM/MAL/2006.1108. 
 IPT in schoolchildren, Version 1.3, 17 March 2008 
 
36 
42. Greenhouse B, Myrick A, Dokomajilar C, Woo JM, Carlson EJ, Rosenthal PJ, Dorsey 
G. Validation of microsatellite markers for use in genotyping polyclonal 
Plasmodium falciparum infections. Am J Trop Med Hyg 2006;75(5):836-42. 
43. Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary, ordered 
categorical, and continuous outcomes in two group comparisons. Bmj 
1995;311(7013):1145-8. 
44. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance 
of rigorous methods. Bmj 1996;313(7048):36-9. 
45. Phillips-Howard PA, West LJ. Serious adverse drug reactions to pyrimethamine-
sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. Journal of 
the Royal Society of Medicine 1990;83(2):82-85. 
46. Miller K, Lobel H, Satriale R, Kuritsky J, Stern R, Campbell C. Severe cutaneous 
reactions among American travelers using pyrimethamine- sulfadoxine (Fansidar) 
for malaria prophylaxis. Am J Trop Med Hyg 1986;35:451-458. 
47. Sturchler D, Mittelholzer ML, Kerr L. How frequent are notified severe cutaneous 
adverse reactions to Fansidar? Drug Safety 1993;8(2):160-68. 
48. Luzzi GA, Peto TEA. Adverse effects of antimalarials. Drug Safety 1993;8(4):295-
311. 
49. Olliaro P, Nevill C, LeBras J, Ringwald P, Mussano P, Garner P, Brausseur P. 
Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 
1996;348:1196-1201. 
50. Brasseur P, Guiguemde R, Diallo S, Guiyedi V, Kombila M, Ringwald P, Olliaro P. 
Amodiaquine remains effective for treating uncomplicated malaria in west and 
central Africa. Transactions of the Royal Society of Tropical Medicine and 
Hygiene 1999;93(6):645-50. 
51. Gorissen E, Ashruf G, Lamboo M, Bennebroek J, Gikunda S, Mbaruku G, Kager PA. 
In vivo efficacy study of amodiaquine and sulfadoxine/ pyrimethamine in 
Kibwezi, Kenya and Kigoma, Tanzania. Tropical Medicine and International 
Health 2000;5(6):459-63. 
52. Staedke S, Kamya M, Dorsey G, Gasasira A, Ndeezi G, Charlebois E, Rosenthal P. 
Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for treatment 
of uncomplicated falciparum malaria in Kampala, Uganda: a randomized trial. 
Lancet 2001;358:368-74. 
53. van Dillen J, Custers M, Wensink A, Wouters B, van Voorthuizen T, Voorn W, Khan 
B, Muller L, Nevill C. A comparison of amodiaquine and sulfadoxine-
pyrimethamine as first-line treatment of falciparum malaria in Kenya. 
Transactions of the Royal Society of Tropical Medicine and Hygiene 
1999;93(2):185-88. 
54. Meshnick SR, Taylor TE, Kamchonwongpaisan S. Artemisinin and the antimalarial 
endoperoxides: from herbal remedy to targeted chemotherapy. Microbiology 
Review 1996;60(2):301-15. 
55. Leonardi E, Gilvary G, White N, Nosten F. Severe allergic reactions to oral 
artesunate: a report of two cases. Trans R Soc Trop Med Hyg 2001;95:182-183. 
56. Kissinger E, Hien TT, Hung NT, Nam ND, Tuyen NL, Dinh BV, Mann C, Phu NH, 
Loc PP, Simpson JA, White NJ, Farrar JJ. Clinical and neurophysiological study 
 IPT in schoolchildren, Version 1.3, 17 March 2008 
 
37 
of the effects of multiple doses of artemisinin on brain-stem function in 
Vietnamese patients. Am J Trop Med Hyg 2000;63(1-2):48-55. 
57. Van Vugt M, Angus BJ, Price RN, Mann C, Simpson JA, Poletto C, Htoo SE, 
Looareesuwan S, White NJ, Nosten F. A case-control auditory evaluation of 
patients treated with artemisinin derivatives for multidrug-resistant Plasmodium 
falciparum malaria. Am J Trop Med Hyg 2000;62(1):65-69. 
58. Price R, van Vugt M, Phaipun L, Luxemburger C, Simpson J, McGready R, ter Kuile 
F, Kham A, Chongsuphajaisiddhi T, White N, Nosten F. Adverse effects in 
patients with acute falciparum malaria treated with artemisinin derivatives. Am J 
Trop Med Hyg 1999;60(4):547-55. 
59. van Vugt M, Ezzet F, Nosten F, Gathmann I, Wilairatana P, Looareesuwan S, White 
NJ. No evidence of cardiotoxicity during antimalarial treatment with artemether-
lumefantrine. Am J Trop Med Hyg 1999;61(6):964-7. 
60. Brewer T, Peggins J, Grate S, Petras J, Levine B, Weina P, Swearengen J, Heiffer M, 
Schuster B. Neurotoxicity in animals due to arteether and artemether. Trans R Soc 
Trop Med Hyg 1994;88(Suppl 1):33-36. 
61. Brewer TG, Grate SJ, Peggins JO, Weina PJ, Petras JM, Levine BS, Heiffer MH, 
Schuster BG. Fatal neurotoxicity of arteether and artemether. Am J Trop Med Hyg 
1994;51(3):251-9. 
62. Genovese R, Newman D, Brewer T. Behavioral and neural toxicity of the artemisinin 
antimalarial, arteether, but not artesunate and artelinate, in rats. Pharmacol 
Biochem Behav 2000;67(1):37-44. 
63. Genovese RF, Newman DB, Li Q, Peggins JO, Brewer TG. Dose-dependent 
brainstem neuropathology following repeated arteether administration in rats. 
Brain Res Bull 1998;45(2):199-202. 
64. Kamchonwongpaisan S, McKeever P, Hossler P, Ziffer H, Meshnick SR. Artemisinin 
neurotoxicity: neuropathology in rats and mechanistic studies in vitro. Am J Trop 
Med Hyg 1997;56(1):7-12. 
65. Li QG, Brueckner RP, Peggins JO, Trotman KM, Brewer TG. Arteether 
toxicokinetics and pharmacokinetics in rats after 25 mg/kg/day single and 
multiple doses. Eur J Drug Metab Pharmacokinet 1999;24(3):213-23. 
66. Nontprasert A, Nosten-Bertrand M, Pukrittayakamee S, Vanijanonta S, Angus BJ, 
White N. Assessment of the neurotoxicity of parenteral artemisinin derivatives in 
mice. Am J Trop Med Hyg 1998;59(4):519-22. 
67. Nontprasert A, Pukrittayakamee S, Nosten-Bertrand M, Vanijanonta S, White N. 
Studies of the neurotoxicity of oral artemisinin derivatives in mice. Am J Trop 
Med Hyg 2000;62(3):409-12. 
68. Petras JM, Kyle DE, Gettayacamin M, Young GD, Bauman RA, Webster HK, 
Corcoran KD, Peggins JO, Vane MA, Brewer TG. Arteether: risks of two-week 
administration in Macaca mulatta. Am J Trop Med Hyg 1997;56(4):390-6. 
69. Nontprasert A, Pukrittayakamee S, Dondorp AM, Clemens R, Looareesuwan S, 
White NJ. Neuropathologic toxicity of artemisinin derivatives in a mouse model. 
Am J Trop Med Hyg 2002;67(4):423-9. 
70. Wesche DL, DeCoster MA, Tortella FC, Brewer TG. Neurotoxicity of artemisinin 
analogs in vitro. Antimicrob Agents Chemother 1994;38(8):1813-9. 
 IPT in schoolchildren, Version 1.3, 17 March 2008 
 
38 
71. Genovese RF, Newman DB, Gordon KA, Brewer TG. Acute high dose arteether 
toxicity in rats. Neurotoxicology 1999;20(5):851-9. 
72. Riberio IR, Olliaro PL. Safety of artemisinin and its derivatives. Med Trop 
1998;58:50-53. 
73. Miller L, Panosian C. Ataxia and slurred speech after artesunate treatment for 
falciparum malaria. New England Journal of Medicine 1997;336:1328-29. 
74. Denis MB, Davis TM, Hewitt S, Incardona S, Nimol K, Fandeur T, Poravuth Y, Lim 
C, Socheat D. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in 
Cambodian children and adults with uncomplicated falciparum malaria. Clin 
Infect Dis 2002;35(12):1469-76. 
75. Karunajeewa H, Lim C, Hung TY, Ilett KF, Denis MB, Socheat D, Davis TM. Safety 
evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in 
Cambodian children and adults with malaria. Br J Clin Pharmacol 2004;57(1):93-
9. 
76. Tran TH, Dolecek C, Pham PM, Nguyen TD, Nguyen TT, Le HT, Dong TH, Tran 
TT, Stepniewska K, White NJ, Farrar J. Dihydroartemisinin-piperaquine against 
multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised 
clinical trial. Lancet 2004;363(9402):18-22. 
77. Ashley EA, Krudsood S, Phaiphun L, Srivilairit S, McGready R, Leowattana W, 
Hutagalung R, Wilairatana P, Brockman A, Looareesuwan S, Nosten F, White 
NJ. Randomized, controlled dose-optimization studies of dihydroartemisinin-
piperaquine for the treatment of uncomplicated multidrug-resistant falciparum 
malaria in Thailand. J Infect Dis 2004;190(10):1773-82. 
78. Ashley EA, McGready R, Hutagalung R, Phaiphun L, Slight T, Proux S, Thwai KL, 
Barends M, Looareesuwan S, White NJ, Nosten F. A randomized, controlled 
study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the 
treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect 
Dis 2005;41(4):425-32. 
 
 
Sensitization and education about the study
Meetings with school staff and parents/guardians of participating schools
Information sheets will be distributed and written informed consent will be sought
from parents/guardians of children aged > 8 years, enrolled in classes 1-7
Informed consent
Children for whom written informed consent is provided by their parent/guardian 
will be assigned a study number and will undergo further screening
Screening at participating schools
Children will be screened for the following selection criteria: 
No onset of menstruation (in girls), provision of assent 
Clinical and laboratory screening
Children who meet the above criteria will be screened for additional criteria: 
Temperature < 38.0°C, no history of fever in past 24 hours, 
No evidence of severe malaria or danger signs, Hb > 7.0 g/dL, pd < 10,000/ul
Enrollment and randomization
If all selection criteria are met, child will be enrolled, and randomized to treatment
with one of four study treatments (SP, AQ+SP, DP, and placebo)
Treatment and blinding
Directly observed therapy administered by study nurses on days 0, 1, and 2.
All study personnel (except study nurses), participating children, their parents/
guardians, and school staff will be blinded.
APPENDIX A: SCREENING AND ENROLLMENT
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APPENDIX B. INFORMATION SHEET 
 
Study Title: IPT in schoolchildren: Comparison of the efficacy, safety, and 
tolerability of antimalarial regimens 
Introduction 
The Uganda Malaria Surveillance Project, the London School of Hygiene and Tropical Medicine, and the Vector 
Control Division of the Uganda Ministry of Health are doing a research study. We would like to see how well 
different malaria medicines work to treat and prevent malaria in schoolchildren. To do this, we are carrying out a 
research study in at least 760 children aged 8 to < 14 years (boys) and 8 to < 12 years (girls) attending primary 
schools in Nagongera sub-county in Tororo, Uganda. From this study we will learn more about how to control 
malaria.  
 
The study staff, Dr. Sarah Staedke and members of the Uganda Malaria Surveillance Project and the Vector Control 
Division, will explain this study to you. Research studies include only people who choose to take part.  Please take 
your time to make your decision about letting your child take part, and discuss your decision with others if you 
wish. If you have any questions, you may ask the researchers. 
 
Why is this study being done? 
Malaria is one of the most important health problems in Uganda. Illness from malaria may prevent children from 
attending school. Children can also be infected with malaria without feeling sick. Malaria infection of any kind may 
impact on a child’s health and their performance at school. We would like to know more about how to prevent and 
treat malaria in schoolchildren. We would like to know which malaria medicines work the best. We would also like 
to know which malaria medicines are tolerated the best, and cause the fewest side effects.  
 
What will happen if I agree to let my child take part in this study today? 
If you agree to let your child (or children) take part in this study, we will ask you to give us directions to your 
house, and will make plans to see your child at his/her school. At the school, the study doctors will talk to your 
child, and will ask your child if he/she agrees to take part in the study. The study doctors will also examine your 
child and take a blood sample by fingerprick to examine for malaria parasites, and to measure the blood level. If 
your child meets all of the criteria for entry into the study, they will be enrolled. The study doctors may exclude 
your child from the study for the following reasons: 
 If your child (girls only) has started to menstruate 
 If your child refuses to take part in the study 
 If your child has fever or tells the study doctors that they have had fever in the past 24 hours 
 If your child has severe malaria or danger signs 
 If your child is currently receiving antimalarial treatment 
 If your child has severe anemia with a hemoglobin of < 7.0 g/dL 
 If your child has malaria with a high parasite count (> 10,000/ul) 
 
What will happen if my child is enrolled in this study? 
If your child (or children) is enrolled into the study, they will be treated with sulfadoxine-pyrimethamine 
(Fansidar), or amodiaquine (Camoquin) plus sulfadoxine-pyrimethamine (Fansidar), or dihydroartemisinin-
UCSF
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piperaquine (Duocotecxin), or placebo. A placebo is a pill that does not have medicine inside of it. Treatment will 
be given at school for three days. The treatment that your child will receive will be determined by a lottery. The 
chance of being placed into each of the treatment groups is the same. You will not be told which treatment your 
child has been assigned to receive.   
 
Your child will be followed for a total of 42 days to see how well the medicines work to treat and prevent malaria. 
The following will take place: 
 The study doctors will examine your child at his/her school at least 8 times so we can administer the treatments, 
judge how well the treatments have worked, and see how well your child has tolerated the medicines.  
 Blood samples will be collected on at least 6 days. Approximately 6 drops of blood will be taken by fingerprick 
to examine for malaria parasites, to measure the blood count, and to store blood samples on paper for future 
laboratory tests that will not impact on the health care of your child. 
 A stool sample will be collected to measure for worm infections. 
 If your child misses an appointment, the home health visitor will visit you at your home to find out why your 
child missed the appointment and to arrange follow-up for your child. 
 If, at any time, the treatment given to your child does not seem to be working well, it will be changed to 
Coartem or quinine. Coartem is the government recommended therapy for treatment of malaria, and quinine is 
recommended for patients with severe malaria. Your child may develop malaria that is severe even after 
receiving treatment with study medications.  If your child shows any evidence of severe malaria (including 
persistent vomiting, low blood counts, shaking or fits, confusion, or you cannot wake your child) your child will 
be referred for possible admission to hospital. 
 If your child gets sick at any time while they are taking part in the study, he/she should let the teachers and the 
study team know. You should seek care for your child from the study team at school, or go to Nagongera Health 
Center or hospital, if school is not in session. 
 
How long will my child be in the study? 
You are being asked to allow your child to take part in this study for up to 42 days or until such a time as you or the 
study doctors decide that your child should no longer take part in the study. The study doctors may withdraw your 
child from the study for the following reasons: 
 If you chose to withdraw your consent to have your child take part in the study 
 If we are unable to locate your child for both doses of study medications, or for follow-up appointments 
 
What risks can I expect if my child takes part in the study? 
 Which treatment your child is given will be determined by chance.  The treatment your child receives may prove 
to be less effective or have more side effects than the other study treatment or than other available treatments. 
This will not be known until after the study is completed. 
 Serious health problems have rarely been reported following treatment with the study medications.  
Sulfadoxine-pyrimethamine (Fansidar) – itching, rash, gastrointestinal reactions (stomach upset), headache, 
convulsions, dizziness, weakness, malaise (general unwell feeling); Amodiaquine (Camoquin) –  nausea, 
vomiting, diarrhea, lethargy (tiredness); Dihydoartemisinin-piperaquine (Duocotecxin) – nausea, diarrhea, 
vomiting, abdominal pain, anorexia, itching, rashes, and dizziness may occur occasionally (1-10% of the time) 
in patients.  
 Your child will be monitored closely after receiving treatment for malaria with the study medications for any 
possible side effects of the drugs and will receive appropriate medical care for any such problem during the 
course of the study.  If your child develops severe shaking or fits, is having trouble breathing, cannot eat, drink, 
or breast feed, or cannot be woken from sleep, they should be brought to the clinic or hospital as soon is 
possible. 
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 The risks of drawing blood from a fingerprick include temporary discomfort, bruising, skin infection, and 
fainting. The amount of blood removed will be too small to affect your child’s health. 
 The research treatments may have side effects that no one knows about yet.  The researchers will let you know if 
they learn anything that might make you change your mind about your child’s participation in the study.  
 
Are there benefits if my child takes part in the study? 
 The potential benefit to your child is that the treatment received may prove to be more effective than the other 
study treatments or than other available treatments, although this cannot be guaranteed.   
 Your child will receive clinical care from the medical officers and nurses of the study staff.  This will include 
care for unscheduled sick visits. 
 The knowledge gained from this study will help the country of Uganda in determining the best way to treat and 
prevent malaria in schoolchildren.   
 
What other choices do I have if I do not allow my child take part in this study? 
You are free to choose not to let your child take part in the study.  If you decide not to take part in this study, there 
will be no penalty to you.   
 
Will information about me and my child be kept private? 
All information gathered will be treated as private by the study personnel, and records will be kept securely in 
locked filing cabinets and offices. No personal identification information such as names will be used in any reports 
arising out of this research. We will do our best to make sure that the personal information gathered for this study is 
kept private. However, any study monitors assigned to this study may look at the information you provide. If 
information from this study is published or presented at scientific meetings, your name and other personal 
information will not be used. 
 
Who pays for this study?  
The Gates Malaria Partnership has funded this study. 
 
What are the costs of taking part in this study?  Will I be paid for taking part in this study? 
There are no costs to you for taking part in this study. You will not be paid for taking part in this study. 
 
Can I stop my child from being in the study? 
You can decide to withdraw your child from the study at any time. Just tell the study researcher right away if you 
wish your child to stop being in the study. 
 
What are my rights if my child takes part in this study? 
Taking part in this study is your choice. You may choose for your child to either to take part or not to take part in 
the study. If you decide for your child to take part in this study, you may change your mind at any time.  No matter 
what decision you take, there will be no penalty to you in any way. 
 
Who can answer my questions about the study? 
You can talk to the researchers about any questions or concerns you have about this study.  Contact Dr. Sarah 
Staedke or other members of the Uganda Malaria Surveillance Project on telephone number 0414-530692. If you 
have any questions, comments or concerns about taking part in this study, first talk to the researchers.  If for any 
reason you do not wish to do this, or you still have concerns about doing so, you may contact the Dr Elly Katabira, 
Makerere University Research and Ethical Committee at telephone number 0414-530020. 
 
APPENDIX C: RESEARCH PARTICIPANT INFORMED CONSENT FORM 
 
 
Protocol Title:  IPT in school children: Comparison of the efficacy, safety, and 
tolerability of antimalarial regimens 
Site of Research: Tororo, Uganda 
Principal Investigator: Sarah Staedke 
Date:    17 March 2008 
I, being of 18 years or older and having full capacity to consent for the children named below, have been informed about this study. 
The nature, duration, purpose, voluntary nature and inconveniences or hazards that may reasonably be expected have been fully 
explained to me.  I have understood the information regarding the study, and what will happen. I have been given the opportunity to 
ask questions concerning this study, and these (if any) have been answered to my satisfaction.  
 
I understand that I may at any time during the study, withdraw my consent and withdraw the subject, without any loss or penalty. My 
refusal to participate will involve no penalty or loss of benefits to which my family are otherwise entitled. 
 Mark one box with X: 
 
I DO CONSENT:                       I hereby agree to allow my child/children take part in this study 
 
I DO NOT CONSENT:               I do not wish my child/children to participate in this study 
 
Parent/Guardian’s 
name 
 
 
Parent/Guardian’s 
Signature or Mark 
 
  
Date: 
 
Village  
 
 
Identity card number 
 
 
Child’s name  
1. 
Class Date of 
birth 
Age 
 
2. 
   
 
3. 
   
 
 
List names of all 
children  
 
 
 
 
4. 
   
 
Witness: I hereby confirm that the study has been explained to the parent/guardian. All questions (if any) have also been answered to 
his/her satisfaction, and he/she has, of his own free will, consented for his child/children to take part in the study. 
Name of Witness:                                                                              
Signature of Witness:                                                                              Date:  
 
Name of person explaining study:  
Signature:                                                                              Date:  
School:  
 
 
APPENDIX C: FORM MANYUTHO YEYO GI ‘NGEYO IGIMA IMENYO TIENDE 
 
 
Nyinge Maradier: IPT inyithidho masikulu: ki piima tich payBero, koodi tich payath 
gi chik mere 
Kama lebedoiye:  Tororo, Uganda 
Jadwar tiende madwong: Sarah Staedke 
Ka:                               17 March 2008 
 
An, bedo angata oro 18 kosa loyo koodi bedo gi meni jie mayeyo ri nyithindho mundiki nyingin piny ka, owachi rani kwongi kisoma 
me. Ngeri,hongo,atonga, ngeri mamiyiroki koodi chandiroki kosa gima kin’gere ma inyalo ngitcho kwonge bedo ochowi tito rani. 
Atyeko niagi wachi ma makere gi kisoma, gi gima latimere. Omiyani silwanyi penjo penji ma mako kwongi kisoma, aka gime (kinen 
nitye) ochowi dwoko muniangani. 
 
Aniag ni anyalo sawa moro jie ihongo makisoma, wiro paro parani gi weyo kiri wach no, mungoye gima arwenyo kosa girachula. 
Kwero parani bedo lengoye iye girachula kosa keng limi moro mapecho parani oyido ripo limo. 
 Kethi ranyuthi isanduku achieli gi chali me X: 
 
AYERE:                        Ayere gi weyo nyathparani/nyithindho bedo ikisoma me 
 
AKIYERE:                Akiyere nyathparani/nyithidho bedo ikisoma me 
 
Nyigi Janu’ol/jakur 
 
 
 
Chingi janu’ol/jakur 
 
  
Ndelo dwe: 
 
Chalo 
 
 
Namba Ma adentikadi 
 
 
Nyingi nyathi      
1. 
Kilas Ndelo 
munyu’ol 
 
Oro 
 
 
2. 
   
 
3. 
   
 
 
Ndiko Ma nyingi 
nyithindho jie  
 
 
 
4. 
   
 
Mujulisi: Aridho ni kisoma me otiti rijanyu’ol/jakur.Penji jie kanitye ochowi dwoko muniango go, aka go, kwong mito pere, oyeyo 
nyithindho/nyathi pere bedo ikisoma me. 
 
Nyingi mujulisi:                                                                              
Chingi mujulisi:                                                                                                                               Ndelo dwe:  
 
Nyingi ngata tito kisoma:  
Chingi:                                                                                                                        Ndelo dwe:  
Sikulu:  
 
 APPENDIX C: INFORMED CONSENT FOR FUTURE USE OF BIOLOGICAL 
SPECIMENS 
 
 
Protocol Title:  IPT in school children: Comparison of the efficacy, safety, and 
tolerability of antimalarial regimens 
Site of Research: Tororo, Uganda 
Principal Investigator: Sarah Staedke 
Date:    17 March 2008 
 
 
INTRODUCTION 
While your child is in this study, blood samples may be taken that may be useful for future research.  These samples 
will be stored long-term at Makerere University Medical School, the London School of Hygiene and Tropical 
Medicine, and the University of California, San Francisco.  Samples may also be shared with investigators at other 
institutions.   
 
WHAT SAMPLES WILL BE USED FOR  
Your child’s blood and the malaria parasites in it will be used to study malaria and the response of this disease to 
treatment.  Results of these studies will not affect your child's care.   
1. These samples will be used for future research to learn more about malaria and other diseases. 
2. Your child’s samples will be used only for research and will not be sold or used for the production of 
commercial products.   
3. Genetic research may be performed on samples.  However, no genetic information obtained from this research 
will be placed in your child’s medical records.  These samples will be identified only by codes so that they 
cannot be readily identified with your child.    
4. For any future genetic studies done on your child’s samples not related to the current study, permission will first 
be sought from the appropriate committee, including the Makerere University Research and Ethics Committee 
Institutional Review Board, the London School of Hygiene and Tropical Medicine Ethics Committee, or the 
University of California, San Francisco Committee on Human Research. 
 
LEVEL OF IDENTIFICATION 
Your child’s samples will be coded so that the child’s name cannot be readily identified.  Reports about research 
done with the samples will not be put in the medical record and will be kept confidential to the best of our ability.   
 
In the future, researchers studying your child’s samples may need to know more about your child, such as 
information about age and gender.  If this information is already available because of your child’s participation in a 
study, it may be provided to the researcher.  Your child’s name or anything that might identify you/them personally 
will not be provided.   You will not be asked to provide additional consent. 
  
 
RISKS  
There are few risks to your child from future use of the samples.  A potential risk might be the release of information 
from your child’s health or study records.  Reports about research done with your child’s samples will not be put in 
the health record, but will be kept with the study records.  The study records will be kept confidential as far as 
possible.   
 
BENEFITS 
There will be no direct benefit to your child.  From studying your child’s samples we may learn more about malaria 
or other diseases: how to prevent them, how to treat them, how to cure them.   
 
RESEARCH RESULTS/MEDICAL RECORDS  
1. Results from future research using your child’s samples may be presented in publications and meetings but 
patient names will not be identified. 
2. Reports from future research done with your child’s samples will not be given to you or the doctor.  These 
reports will not be put in your child’s medical record. 
 
QUESTIONS 
The future use of your child’s specimens has been explained to you by the person who signed below and your 
questions were answered.  If you have any other questions about the information here, you may call Dr. Sarah 
Staedke (0414-530692) at the MU-UCSF Research Collaboration offices. 
 
FREEDOM TO REFUSE 
You can change your mind at any time about allowing your child’s samples to be used for future research.  If you 
do, contact Dr. Sarah Staedke (0414-530692) at the MU-UCSF Research Collaboration offices. Then your child’s 
samples will no longer be made available for research and will be destroyed. Whether or not you allow us to use 
your child’s samples in future research will not have any effect on your child’s participation in this study or future 
participation in other studies. 
 
WHAT YOUR SIGNATURE OR THUMBPRINT MEANS 
Your signature or thumbprint below means that you understand the information given to you in this consent form 
about your child’s specimens and cultures to be used for future research.  If you wish to allow your child’s 
specimens and cultures to be used for future research, you should sign or thumbprint below. 
 Mark one box with X: 
 
 
I DO CONSENT:          
 I hereby agree to allow my child’s/children’s specimens and 
cultures to be used for future research 
 
I DO NOT CONSENT:         
 I do not wish my child’s/children’s specimens and cultures to be 
used for future research 
 
Parent/Guardian’s 
name 
 
 
Parent/Guardian’s 
Signature or Mark 
 
  
Date: 
 
Village  
 
 
Identity card number 
 
 
Child’s name  
1. 
Class Date of 
birth 
Age 
 
2. 
   
 
3. 
   
 
 
List names of all 
children  
 
 
 
 
4. 
   
 
 
Witness: I hereby confirm that the study has been explained to the parent/guardian. All questions (if any) have also 
been answered to his/her satisfaction, and he/she has, of his own free will, consented for his child/children’s 
specimens and cultures to be used for future research.  
 
Name of Witness:                                                                              
Signature of Witness:                                                                              Date:  
 
 
Name of person explaining 
study: 
 
Signature:                                                                              Date:  
School:  
 
 
 
APPENDIX C: NG’EYO IYEYO MAYUWANGE ILA 
ORO MA   FONJIROK KWONGE  PAKA  GIRANENA  WOKI KWONG  WADI 
 
 
Nyinge Maradier: IPT inyithidho masikulu: ki piima tich payBero, koodi tich 
payath gi chik mere 
Kama lebedoiye:  Tororo, Uganda 
Jadwar tiende madwong: Sarah Staedke 
Ka:                               17 March 2008 
 
 
CHAKIROK MERE 
Ka nyathi perin nitye ikisoma me, ilakwanyo remo minyalo medo menyotiende yuwange.Remo mukwanyi me 
ilakano mahongo mathothi iodi kisoma mukadhomalo ma makerere, sikulu ma lonyo giyath matwoo kama piny 
liethye ma London, koodi ka kisoma mukadhomalo ma California,San Francisco. Remo mukwanyi me bende inyalo 
lewo gi juma bende dwaro tiend twoo ma kakisoma mani-man. 
 
GIMA OKWANYI NO NGERI MILE ORO GINE 
Remo panyathi perin kudin makelo musuja manitye iye ile oro ma kisoma  kwong musuja gi ‘ngeri ma twoo me 
bedo gine ka omiyi yath/konyi.Gima owoki kwong kisoma me kila nyeko miyo nyathiperin konyi. 
1. Gima okwanyi ma kisoma kwonge me ile oro mafonjirok kwonge yumalo ma niang kwong musuja gitwoo 
mani-manijie. 
2. Gima okwanyi kwongi nyathiperin me ila oro nyaka ma menyo tiende gi fonjirok Kwonge to kila kitana 
kosa oro matimo gimorojie makelo pesa. 
3. Wanyolo menyo tiendi pek gi dongo maremo woki kwongi gima okwanyi. Too, ongoye wach  ma kula 
kosa kite mu’pondo manitye inyathi perin maile ketho ibaliwa pere ma limo yath/kony. Gima okwanyi. Me 
ile ketho kwonge namba nyaka ma ngeyo gine ma chero kwako ngeyoni kole a’gima okanyi kwongi nyath 
perin  mu’ngoye kigana-gana. 
4. Ikisoma kosa medo menyo kite mupondo yuwange igima okwanyi kwong nyathi.  Perin makichale gima 
isoma pama, meni kutho ile kwanyo bongi komiti, kanya’chiel gi komiti ma Makerere kakisoma 
mukadhomalo imeyo tiendi twoo koodikitemaraluwa, komiti ma sikulu malonyo gi yeni makama pinyi 
liethye ma London, kosa komiti ma California ka kisoma ma malo,San Francisco imenyo tiendi jii. 
 
NGERI MA’GEYO                              
Wale ketho namba igima okwanyi kwong nyathperin magengo kwako ngeyo nyingi nyath perin. Wakila ketho gima 
owoki kwongi fonjirok kwong gima okwany kwong nyayhi perin ibaliwa pere ma madho yathi/limo kony aka 
ilekano paka nyaling-ling gi kama wanyalo gine jie. 
 
Jumenyi tiendi twoo ma soma kwong gima okwany kwong nyathi perin  yumalo nyalo mito ngeyo mathothi kwong 
nyathi perin, Nger wachino nyalo bedo paka oro, koodi nyathi manedi [nyako kosa jachwo]. Wanyalo miyojo ngeyo 
iwachino ka nitye woki kwong bedo panyath perin ikisoma me. Wakila miyo jo nyingi nyathiperin kosa gimorojie 
manyalo mio ngitcho/ngeyo ini/ nyathindho no. Wakila doko mito ni ikethi chingin iformi manyutho yeyo man. 
 
JWANGIROK 
Juwangirok nitye manoki rinyathiperin  aka meno oro nyaka gime okwanyi kwonge yumalo. Juwangirok mutire 
nyalo bedo wodho wachi kwong kwoo panyathiperin kosa kopi ma ikano ma kisoma. Wakile ketho radwok ma woki 
kwong fonjirok mu’otim kwong gima okwany kwong nyathiperin ibaliwa ma okan matucho nyaling-ling makwo 
pere. Wale kano radwoki me kanya’chiel gi kopi magima owoki kwong kisoma pakanyaling-ling aka maber  paka 
wanyalo. 
 
LIMI  
Nyathiperin Kila limo mutire kwongi fonjirok me. Woki kwong kisoma kwong gima okwany kwongi nyathiperin, 
wanyalo fonjere mathothi kwong musuja kosa twoo mani-manjie:Wanyalo fonjere ngeri magen’go jo,miyokonyi, 
gibotho jo. 
 
RADWOK MAGIMA IMENYO TIENDE /KOPI MA MAKO KWONG KWO 
1. Wanyalo wodho yuwange gima owoki kwong medo oro /fonjirok kwong gima okwa nyi kwong nyathi 
perin ipapula kodi iromo to nyigi jatwoo kila’ngeyo. 
2. Radwok kwong fonjirok ma yuwange mutim kwong gima okwanyi kwong nyathi perin kilamiyin kosa 
musawo pere. Wakila ketho radwok me ifilo kosa kopi malimo konyi panyathiperin. 
 
PENJI  
Oro gima okwanyi kwong nyath perin yuwange ngata oketho nyinge pinyi ka ochowo tito rini aka penji perin 
odwok. Ka initye gipenji mani-man jie mamako kwong wachi  manitye ka,inyalo lwongo musawo Sarah Staedke 
inamba me (0414-530692) I MU-UCSF offisi ma gima’menyo tiende romo’iye. 
 
INIGI THWOLO MA KWERO 
Initye gi thwolo ma wiro paro perin kwong oro gimo’okwanyi kwongi nyath perin ma fonjiroki kwonge yuwange 
sawa morojie.Ka iwiro paro perin,romi gi musawo Sarah Staedke isimo me (0414-530692) I MU-UCSF offisi ma 
gima imenyo tiende romo’iye.Go le temo swa ni gima okwanyi kwong nyathiperin onyek woko maku’odoko odong 
ma menyo tiende yuwange. Kada iyeyo kosa ikiyeyo wan oro gima okwany kwong nyath perin yuwange kila nyeko 
bedo panyath perin ikisoma me kosa mabino yumalo. 
 
GIMA CHINGIN MIKETHO / IFUYO NYUTHO 
Chingin miketho kosa ifuyo pinyi ka nyutho ni iniang wach mumiyin ka iformi manyutho yerok me mamako kwong 
gime okwanyi mara’ora kwong nyathi perin gi thene-thene mere mafonjirok yumalo. Ka imto yeyo gima okwanyi 
kwong nyath perin githene-thene mere ‘ori ma medo fonjirok kwonge yuwange, iripo ketho / fuyo chingin piny ka. 
 
 Kethi ranyuthi isanduku achieli gi chali me X: 
 
 
AYERE:                  
 I hereby agree to allow my child’s/children’s specimens and 
cultures to be used for future research 
 
AKIYERE:          
 I do not wish my child’s/children’s specimens and cultures to be 
used for future research 
 
Nyigi Janu’ol/jakur 
 
 
 
Chingi janu’ol/jakur 
 
  
Ndelo dwe: 
 
Chalo 
 
 
Namba Ma adentikadi 
 
 
Nyingi nyathi      
1. 
Kilas Ndelo 
munyu’ol 
 
Oro 
 
 
2. 
   
 
3. 
   
 
 
Ndiko Ma nyingi 
nyithindho jie  
 
 
 
4. 
   
 
Mujulisi: Aridho ni kisoma me otiti rijanyu’ol/jakur.Penji jie kanitye ochowi dwoko muniango go, aka go, kwong mito pere, 
oyeyo nyithindho/nyathi pere bedo ikisoma me. 
 
Nyingi mujulisi:                                                                              
Chingi mujulisi:                                                                                                                               Ndelo dwe:  
 
 
Nyingi ngata tito kisoma:  
Chingi:                                                                                                                        Ndelo dwe:  
Sikulu:  
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APPENDIX D: INITIAL SCREENING FORM (1) 
 
Primary school code:  |_____|_____|  
 
Primary school name: 
 
Screening ID: |_____|_____|_____|_____| 
 
 
Date of screening:                
                                     |____|____|/|____|____|/|____|____| 
                                            day            month          year  
Stude nt’s last name  
 
 
Stude nt’s first name  
Stude nt’s  
initials* 
 
Student’s  
class 
 
Date of birth        |____|____|/|____|____|/|____|____| 
                                    day            month          year 
 
Age :  |_____|_____| years 
 
Gender:    
                        Male        Fe male  
Parent/guardian’s last name  
 
 
Parent/guardian’s first na me  
*Initial of last name, followed by initial of first name 
 
ASSESS DURING SCREENING INTERVIEW WITH PARENT/GUARDIAN 
Se lection criteria Include Exclude 
1. Age > 8 to < 14 years (boys); > 8 to < 12 years (girls) 
  Yes   No 
2. Student enrolled at participating school in classes 1 – 7 
 
 Yes   No 
3. Known allergy or history of adverse reaction to study medications: 
    If present, indicate drug / reaction: 
 Sulfadoxine-pyrimethamine:________________________________ 
 Amodiaquine:____________________________________________ 
 Dihydroartemisinin-piperaquine:_____________________________ 
 
 No   Yes 
4. Onset of menstruation (girls) 
 
 N/A 
 No 
  Yes 
If any boxes in the "Exclude" column are ticked, exclude from the study. If not, proceed to the next section. 
 
 
INFORMED CONSENT DISCUSSION 
Se lection criteria Include Exclude  
5. Willingness of parents or guardians to provide informed consent 
 
  Yes   No 
If the box in the "Exclude" column is ticked, exclude from the study. If not, proceed to the next section. 
 
 
All INITIAL Screening crite ria met?        
           
             Yes    If yes, assign Study ID                                               
             No     If no, exclude from the study  
 
ASSIGN STUDY ID 
 
                              |_____|_____|_____|_____|_____| 
 
 
Completed by: 
                                           
 
Signature: 
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INITIAL SCREENING FORM (2) 
 
Primary school code:  |_____|_____|  
 
Primary school name: 
 
Study ID: |______|______|______|______|______| 
 
 
Date of screening:                
                                     |____|____|/|____|____|/|____|____| 
                                            day            month          year  
Stude nt’s last name  
 
 
Stude nt’s first name  
Parent/guardian’s last name  
 
 
Parent/guardian’s first na me  
 
 
HOUSEHOLD INFORMATION 
Home  parish: 
 
LC1/village: 
Home  address and localizing features: 
 
 
 
 
 
 
 
 
Phone number:   Yes    No     
If yes:  Phone number (s) and the owner (s): 
 
BED NET INFORMATION 
Does your household have any mosquito ne ts that can be  use d while  sleeping? 
  Yes 
  No    If no, skip to end. 
How many mosquito nets does your household have?                    
 
 
|_____|_____| nets 
 
When you got the ne t, was it already factory-treate d with an insecticide  to kill or 
re pel mosquitoes?                                                                                             
  Yes 
  No   
  Not sure 
Since you got the  mosquito net, was it eve r soaked or dipped in a liquid to repel 
mosquitoes or bugs?                                                                                                             
  Yes 
  No   
  Not sure 
How long ago was the ne t last soaked or dipped?  
                                                                                                                                       
Record number of months if < 24 months.  
If less than 1 month ago, record ‘00' months.  
If less than 2 years ago, record number of months ago.  
If ‘12 months ago’ or ‘1 year ago,’ probe for exact number of months. 
 If > 24 months ago, record number of years.  
 
 
|_____|_____|  months ago 
 
 
|_____|_____|  years ago 
 
 
 
Completed by: 
                                           
 
Signature: 
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APPENDIX E: CLINICAL SCREENING FORM 
 
Primary school code:  |_____|_____|  
 
Primary school name: 
 
Screening ID: |_____|_____|_____|_____| 
 
 
Date of screening:                
                                     |____|____|/|____|____|/|____|____| 
                                            day            month          year  
 
Study ID:    |_____|_____|_____|_____|_____|  
 
Stude nt’s initials* 
 
 
Stude nt’s last name  
 
 
Stude nt’s first name  
 
ASSESS DURING SCREENING INTERVIEW 
Se lection criteria Include Exclude 
6. Onset of menstruation (girls)   N/A 
 No 
  Yes 
If the box in the "Exclude" column is ticked, exclude from the study. If not, proceed to the next section. 
 
ASSENT DISCUSSION 
Se lection criteria Include Exclude  
7. Willingness of student to provide assent   Yes   No 
If the box in the "Exclude" column is ticked, exclude from the study. If not, proceed to the next section. 
 
CLINICAL SCREENING 
Selection criteria Include  Exclude 
8. Fever (> 37.5°C axillary) or history of fever in the previous 24 hours   No   Yes 
9. Evidence of severe malaria or danger signs 
If “ YES” indicate criteria. If “NO”, leave blank. 
 Unarousable coma (if after convulsion, > 30 min) 
 Repeated convulsions (> 2 within 24 h) 
 Recent convulsions (1-2 within 24 h) 
 Altered consciousness (confusion, delirium,, coma) 
 Lethargy 
 Unable to drink or breast feed 
 Vomiting everything 
 Unable to stand/sit due to weakness 
 Respiratory distress (labored breathing at rest) 
           Jaundice (yellow coloring of eyes) 
  No   Yes 
10. Ongoing antimalarial treatment   No   Yes 
11. Haemoglobin < 7.0 g/dL   No   Yes 
12. Parasite density > 10,000/ul   No   Yes 
If the box in the "Exclude" column is ticked, exclude from the study. If not, proceed to the next section. 
 
ENROLLMENT 
All criteria for study inclusion me t?         
             Yes                                                    
             No     If no, exclude from the study  
Date  of enrollment (date study begins) 
 
                          |___|___|/|___|___|/|___|___|                                          
                              day         month       year 
 
Completed by: 
                                           
 
Signature: 
 
 
APPENDIX F: RESEARCH PARTICIPANT ASSENT FORM FOR CHILDREN 
 
 
Protocol Title:  IPT in school children: Comparison of the efficacy, safety, and 
tolerability of antimalarial regimens 
Site of Research: Tororo, Uganda 
Principal Investigator: Sarah Staedke 
Date:    17 March 2008 
 
  I am being asked to decide if I want to be in this research study. 
 
  I may be given medicine to treat malaria even if I am not feeling sick today.   
 
  I know that I will have to see the study doctors at least 8 times over the next 6 weeks. The doctors will talk to 
me, ask me questions, and examine me. 
 
  I know I will have a few drops of blood drawn at least 6 times over the next 6 weeks.  
 
  I know that if I get sick during the next 6 weeks I should seek care and let my teachers and the study team know 
that I am sick. I may come to school to see the study doctors, or go to the health center or hospital.  
 
  I asked and got answers to my questions. I know that I can ask questions about this study at any time. 
 
  I know that I can stop being in this study at anytime without anyone being mad at me.  
 
Mark one box with X: 
 
I DO CONSENT:                       I hereby agree to take part in this study 
 
I DO NOT CONSENT:               I do not wish to take part in this study 
 
 
Child’s name 
 
 
 
Childs’s Signature or Mark 
 
  
Date: 
 
Witness: I hereby confirm that the study has been explained to the child. All questions (if any) have also been 
answered to his/her satisfaction, and he/she has, of his own free will, consented to take part in the study. 
Name of Witness:                                                                              
Signature of Witness:                                                                              Date:  
 
Name of person explaining study:  
Signature:                                                                              Date:
School:  
 
 
APPENDIX F: FORMI MAYEROK PANYITHINDHO BEDO IMENYO TIENDI TWOO 
 
 
Nyinge Maradier: IPT inyithidho masikulu: ki piima tich payBero, koodi tich 
payath gi chik mere 
Kama lebedoiye:  Tororo, Uganda 
Jadwar tiende madwong: Sarah Staedke 
Ka:                               17 March 2008 
   
  Ikwayan yero kamito bedo ikisoma me. 
 
  Inyalo miyan yath ma botho musuja makada ne’nde akawinji ni’atwoo konon. 
 
  Angeyo ni ale neno lactar makisoma me kada di8 isabiti 6. Lactar la luwo kodan, penjan, kanyachiel gi kipiima 
an. 
 
  Angeyo ni ale wodho remo manok moro di5 isabiti 6 mabino. 
 
  Angeyo ni ka anwango twoo ihongo masabiti 6 me aripo limo kony gimiyo jufonji Paran koodi jumatimo 
kisoma me ‘ngeyo ni atwoo. Anyalo bino isikulu lactar ma kisoma, kosa kidho I’od boyh kosa idwaliro. 
 
  Apenjere aka alimo radwok ma penji paran. Angeyo ni anyalo penjo penji ma makere koodi kisoma me sawa 
morojie. 
 
  Angeyo ni anyalo chungo /weyo bedo ikisoma me mungoye ngata oger ran. 
 
Kethi ranyuthi isanduku achieli gi chali me X: 
 
AYERE:                        Ayere ka weyo nyathparan/nyithindho bedo ikisoma me 
 
AKIYERE:                         Akiyere nyathparan/nyithidho bedo ikisoma me 
 
 
Nyingi nyath  
 
 
 
Chingi / nyathi  
 
  
Ndelo dwe: 
 
 
Mujulisi: Aridho ni kisoma me otiti rijanyu’ol/jakur.Penji jie kanitye ochowi dwoko muniango go, aka go, kwong mito pere, 
oyeyo nyithindho/nyathi pere bedo ikisoma me. 
Nyingi mujulisi:                                                                              
Chingi mujulisi:                                                                                                                     Ndelo dwe:  
 
Nyingi ngata tito kisoma:  
Chingi:                                                                                                              Ndelo dwe:  
Sikulu:  
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APPENDIX G: CLINICAL RECORD 
FORM (1) 
 
School class:  |_____| 
 
Primary school name:  
Student  
Initials: 
 
Study  
Numbe r:  |_____|_____|_____|_____|_____| 
 
Date enrolled (Day 0): |____|____|/|____|____|/|____|____| 
                                               day               month            year  
 
Weight (kg): 
 
Age:   |_____|_____|  years  
 
Gender:    
                      Male        Female 
Known drug allergies      No       Unknown     Yes     If yes, describe: 
 
“Does your household own a bed net?”      
                                                                              Yes         No             Unknown         
“Did you sleep under a bed net last night?”      
                                                                                  Yes        No      Not applicable        
 
SYMPTOM RECORD  (Rank on scale of 0-4: absent = 0; mild = 1; moderate = 2; severe = 3, life-threatening = 4, N/A = unable to assess)         EXTRA FORM USED; YES   NO  
 DAY 0 DAY 1 DAY 2 DAY 3 DAY 7 DAY 14 DAY 28 DAY 42 DAY __ DAY __ DAY __ 
DATE            
Outside treatment (Y/N)*            
Fever in past 24h (Y/N)            
Weakness/fatigue            
Muscle/joint aches            
Headache            
Anorexia            
Nausea            
Vomiting            
Abdominal pain            
Diarrhea            
Cough            
“Flu”            
Pruritis            
Skin rash            
Tinnitus            
Other______________            
Other______________            
AE reported† (Y/N)                      
Initials            
* If yes, record treatment on CLINICAL RECORD FORM (4) 
† Notify Kampala core facility immediately of all serious adverse events. 
UMSP / LSHTM / VCD    IPT in schoolchildren: Comparison of antimalarial regimens 
 
 
 
       
 
CLINICAL RECORD 
FORM (2) 
Student 
Initials: 
 
Study  
Numbe r:  |_____|_____|_____|_____|_____| 
 
Date enrolled (Day 0): |____|____|/|____|____|/|____|____| 
                                               day              month              year  
 
 
PHYSICAL EXAM RECORD    (Rank on scale of 0-4: normal = 0; mild abnormality = 1; moderate = 2; severe = 3, life-threatening = 4, N/A = unable to assess) 
 DAY 0 DAY 1 DAY 2 DAY 3 DAY 7 DAY 14 DAY 28 DAY 42 DAY __ DAY __ DAY __ 
DATE 
 
           
Temperature (ºC)            
Dehydration            
Jaundice            
Chest            
Abdomen            
Skin            
Tablet test            
Other__________            
Other__________            
AE reported† (Y/N)                      
ABNORMAL EXAM RECORD 
 
If abnormality no ted on physical 
exam, describe all physical 
findings for the abnormal exam 
 
 
 
 
 
 
 
 
 
       
 
    
Initials 
 
           
† Notify Kampala core facility immediately of all serious adverse events. 
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CLINICAL RECORD 
FORM (3) 
Student 
Initials: 
 
Study  
Numbe r:  |_____|_____|_____|_____|_____| 
 
Date enrolled (Day 0): |____|____|/|____|____|/|____|____| 
                                               day              month              year  
 
 
LABORATORY RECORD 
 DAY 0 DAY 1 DAY 2 DAY 3 DAY 7 DAY 14 DAY 28 DAY 42 DAY __ DAY __ 
DATE 
 
          
Parasite density 
(asexual parasites/ul) 
          
Species 
 
          
Gametocyte density 
(gametocytes/ul) 
          
Haemoglobin† (g/dL) 
      [grade] 
 
[     ] 
       
           [     ] 
  
 
Stool sample 
 
          
Initials           
† Any hemoglobin < 5 g/dl measured after Day 0 is a serious AE.  Notify Kampala core facility immediately of all serious adverse events. 
 
RECORD OF ADDITIONAL MEDICATIONS GIVEN DURING STUDY 
Medication (a) Indication (b) Dose (c) Duration (d) Date  started (e) 
1.     
2.     
3.     
4.     
5.     
6.     
7.      
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CLINICAL RECORD 
FORM (4) 
Student 
Initials: 
 
Study  
Numbe r:  |_____|_____|_____|_____|_____| 
 
Date enrolled (Day 0): |____|____|/|____|____|/|____|____| 
                                               day              month              year  
 
 
RECORD OF MEDICATIONS GIVEN OUTSIDE OF THE STUDY 
Medication (a) Indication (b) Dose (c) Duration (d) Date  started (e) 
1.     
2.     
3.     
4.     
 
CLASSIFICATION OF OUTCOME 
 
  Clinical failure            
 
 
Day of failure 
 
|_____|_____| 
 
If clinical failure, indicate reason:   
        **Development of danger signs or severe malaria on Days 0 to 42 in the presence of parasitemia   If yes, specify criteria :_____________________ 
        **Temperature > 37.5C (A), or history of fever in previous 24 hours, on Days 3 to 42 in the presence of parasitemia 
 
 
  Parasitological failure 
 
 
Day of failure 
 
|_____|_____| 
 
 
If parasitological failure, indicate reason:       
        **Development of hyperparasitemia (> 10,000/ul) on Days 1 to 42 
        Presence of parasitemia on Days 4 to 41 and axillary temperature  < 37.5C (A), without previously meeting any of the criteria of clin ical failure 
        **Presence of parasitemia on Day 42 and axillary temperature  < 37.5C (A), without previously meeting any of the criteria of clinical failure 
 
 
  ACPR 
 
  
Defined as: Absence of parasitemia on Day 42 irrespective of temperature without previously meeting any of the criteria for clinical failure or 
parasitological failure 
 
  Withdrawn 
 
 
Day withdrawn 
 
 |_____|_____| 
 
 
If withdrawn, indicate reason:           
        Consent to participate withdrawn 
         Lost to follow-up 
 
   No efficacy outcome 
 
 If no efficacy outcome, indicate reason:             
        Use of antimalaria l drugs outside of the study protocol 
         Incomplete treatment with study medications 
** Requires rescue therapy 
17 March 2008 
 
APPENDIX H. Guidelines for Grading Patient Symptoms, signs and 
laboratory findings 
 
Table A. Guidelines for grading patient symptoms 
 Grade 1 
MILD 
Grade 2 
MODERATE 
Grade 3 
SEVERE 
Grade 4 
LIFE THREATENING 
Subjective 
fever in the 
past 24 h 
N/A Present (Yes) N/A N/A 
Weakness Mild decrease in 
activity; For children – 
weak, but still playing 
Moderate decrease in 
activity; For children – 
weak, and playing 
limited 
Not participating in 
usual activities; For 
children – not playing 
Prostration 
Muscle and/or 
joint aches* 
Mild and/or localized 
complaints 
Diffuse complaints Objective weakness; 
function limited 
N/A 
Headache* Mild, no treatment 
required 
Transient, moderate; 
treatment required 
Severe, constant; 
requires narcotic therapy 
Intractable; requires 
repeated narcotic therapy 
Anorexia Decreased appetite, but 
still taking solid food 
Decreased appetite, 
avoiding solid food but 
taking liquids 
Appetite very decreased; 
Refusing to breast feed, 
no solids or liquids taken 
(< 2 years < 12 hr; > 2 
years < 24 hr) 
Appetite very decreased; 
Refusing to breast feed, 
no solids or liquids taken 
(< 2 years > 12 hr; > 2 
years > 24 hr) 
Nausea* Mild, transient feeling of 
impending vomiting; 
maintains reasonable 
intake 
Moderate and/or 
constant feeling of 
impending vomiting; 
intake decreased  
Severe, constant feeling 
of impending emesis; 
intake decreased 
significantly  
N/A 
Vomiting 1 episode per day 2-3 episodes per day Orthostatic hypotension 
or IV fluids required 
Hypotensive shock or 
 nrolment ation 
required for IV fluid 
therapy 
Abdominal 
pain* 
Mild (1-3 on a scale of 1 
to 10) 
Moderate (4-6 on a scale 
of 1 to 10) 
Moderate to severe (> 7 
on a scale of 1 to 10) 
Severe –  nrolment at 
for treatment 
Diarrhea Transient 3-4 loose 
stools/day 
5-7 loose stools/day Orthostatic hypotension 
or > 7 loose stools/day or 
IV fluids required 
Hypotensive shock or 
 nrolment ation for IV 
fluid therapy required 
Cough Transient / intermittent Persistent / constant Uncontrolled Cyanosis, stridor, severe 
shortness of breath 
Pruritis Transient pruritis  Pruritis that disturbs 
sleep 
Severe, constant pruritis, 
sleep disturbed 
N/A 
Tinnitus* Mild, transient ringing or 
roaring sound 
Moderate, persistent 
ringing or roaring sound 
Severe ringing or roaring 
sound with associated 
hearing loss 
N/A 
Behavioural 
changes 
Mild difficulty 
concentrating; mild 
confusion or agitation; 
activities of daily living 
unaffected; no treatment 
Moderate confusion or 
agitation; some 
limitation of activities of 
daily living; minimal 
treatment 
Severe confusion or 
agitation; Needs 
assistance for activities 
of daily living; therapy 
required 
Toxic psychosis; 
 nrolment ation 
required 
“Flu”  
(viral URI) 
Mild nasal congestion, 
mild rhinorrhea 
Moderate nasal 
congestion, moderate 
rhinorrhea 
N/A  N/A  
Allergic 
reaction 
N/A N/A Urticaria Severe urticaria  
anaphylaxis, angioedema 
Convulsion N/A N/A Localized or generalized 
seizure 
Status epilepticus 
* Assess only in children > 3 years of age.  Answer N/A for younger children and those unable to answer. 
 
Reference – Based on WHO Toxicity Grading Scale for Determining the Severity of Adverse Events 
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Table B. Guidelines for Physical Examination 
 
Dehydration Assess skin touch and turgor, mucous membranes, eyes, crying, fontanelle, pulse, urine output 
 
Jaundice Assess for yellowing of the sclera.  Also evaluate the palpepral conjunctiva, lips, and skin. 
 
Chest Observe the rate, rhythm, depth, and effort of breathing.   Check the patient’s colour for cyanosis. 
 
The maximum acceptable respiratory rate by age: < 2 months = 60, 2-12 months = 50, 1-5 years = 40, 
above 5 years = 30. 
 
Inspect the neck for the position of the trachea, for supraclavicular retractions, and for contraction of 
the sternomastoid or other accessory muscles during inspiration.   
 
Auscultate the anterior and posterior chest for normal breath sounds and any adventitious sounds 
(crackles or rales, wheezes, and rhonchi).  Crackles are intermittent, non-musical, fine or coarse 
sounds that may be due to abnormalities of the lungs (pneumonia, fibrosis, early congestive heart 
failure) or airways (bronchitis or bronchiectasis).  Wheezes are high-pitched and result from 
narrowed airways.  Rhonchi are relatively low-pitched and suggest secretions in large airways.   
 
If abnormalities are identified, evaluate for transmitted voice sounds.  In addition, palpate the chest to 
assess for tactile fremitus, and percuss the chest to assess for areas of dullness.  Normal, air-filled 
lungs emit predominantly vesicular breath sounds, transmit voice sounds poorly with “ee” = “ee”, 
and have no tactile fremitus.  Airless lung, as in lobar pneumonia, emits bronchial breath sounds, 
transmits spoken words clearly with “ee” = “aay” (egophany), and has an increase in tactile 
fremitus. 
 
Abdomen Inspect and ausculate the abdomen.  Listen for bowel sounds in the abdomen before palpating it.  
Palpate the abdomen in all 4 quadrants lightly and then deeply.  Assess the size of the liver and spleen.  
To assess for peritoneal inflammation, look for localised and rebound tenderness, and voluntary or 
involuntary rigidity.  
 
Skin Inspect the skin for colour, turgor, moisture, and lesions.  If lesions are present, note their location and 
distribution (diffuse or localised), arrangement (linear, clustered, annular, dermatomal), type (macules, 
papules, vesicles) and colour.   
 
Tablet test For children > 9 months of age, ask the patient to pick a tablet (or equivalent object) up off a flat 
surface using the thumb and index finger of their dominant hand.  This tests for co-ordination of the 
upper extremity assessing the function of the motor system, cerebellar system, vestibular system (for 
coordinating eye and body movements) and the sensory system, for position sense.  When testing small 
children, be aware that they will likely attempt to put the object into their mouth. 
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Table C.  Grading Physical Examination Findings 
 
 Grade 1 
MILD 
Grade 2 
MODERATE 
Grade 3 
SEVERE 
Grade 4 
LIFE-
THREATENING 
Temperature
* (axillary) 
37.5-37.9C 38.0-39.5C > 39.5C Sustained fever, equal 
or greater than 40.0C 
for longer than 5 days 
Dehydration Less than 2 of the 
following: 
Restless, irritable 
Sunken eyes 
Drinks eagerly, thirsty 
Skin pinch goes back 
slowly 
2 of the following: 
Restless, irritable 
Sunken eyes 
Drinks eagerly, thirsty 
Skin pinch goes back 
slowly 
Two of the following: 
Lethargic or 
unconscious 
Sunken eyes 
Not able to drink or 
drinking poorly 
Skin pinch goes back 
very poorly 
Two of the following + 
shock: 
Lethargic or 
unconscious 
Sunken eyes 
Not able to drink or 
drinking poorly 
Skin pinch goes back 
very poorly 
Jaundice Slight yellowing of 
sclera and conjunctiva 
 
Moderate yellowing of 
sclera and conjunctiva, 
yellowing of mucous 
membranes 
Severe yellowing of 
sclera and conjunctiva, 
yellowing of skin 
N/A 
Chest Mildly increased RR 
(for age, temperature), 
transient or localised 
adventitious sounds 
 
Moderately increased 
RR, diffuse or 
persistent adventitious 
sounds 
Rapid RR (< 2 months 
> 60, 2-12 months > 
50, 1-5 years > 40, 
adults > 30)* nasal 
flaring, retractions 
Cyanosis 
Abdomen Normal bowel sounds, 
mild localised 
tenderness, and/or liver 
palpable 2-4 cm below 
the right costal margin 
(RCM), and/or spleen 
palpable, and/or 
umbilical hernia 
present 
Normal or mildly 
abnormal bowel 
sounds, moderate or 
diffuse tenderness; 
and/or mild to 
moderately enlarged 
liver (4-6 cm below the 
RCM) and/or spleen 
palpable up to half-way 
between umbilicus and 
symphysis pubis 
Severely abnormal 
bowel sounds, severe 
tenderness to palpation.  
Evidence of peritoneal 
irritation and/or 
significant enlargement 
of liver (> 6 cm below 
the RCM) and/or 
spleen palpable beyond 
half-way between 
umbilicus and 
symphysis pubis 
Absent bowel sounds.  
Involuntary rigidity 
Skin† Localised rash, 
erythema, or pruritis 
Diffuse, maculopapular 
rash, dry desquamation 
Vesiculation, moist 
desquamation, or 
ulceration 
Exfoliative dermatitis, 
mucous membrane 
involvement or 
erythema multiforme 
or suspected Stevens-
Johnson or necrosis 
requiring surgery 
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Table C.  Grading Physical Examination Findings (continued) 
 
 Grade 1 
MILD 
Grade 2 
MODERATE 
Grade 3 
SEVERE 
Grade 4 
LIFE-
THREATENING 
Hearing < 4 years: N/A 
> 4 years: Decreased 
hearing in one ear 
< 4 years: N/A 
> 4 years: Decreased 
hearing in both ears or 
severe impairment in 
one ear 
< 4 years: Any 
evidence of hearing 
impairment 
> 4 years:  Severe 
impairment in both 
ears 
N/A 
Tablet test Difficulty grasping 
tablet but able to pick 
up 
Unable to pick up 
tablet without dropping 
Unable to grasp tablet N/A 
Clinical 
symptoms / 
sign (not 
otherwise 
specified) 
No treatment required; 
monitor condition 
Treatment required Requires treatment and 
possible hospitalisation 
Requires active 
medical intervention, 
hospitalisation, or 
hospice care 
 
 
  Reference – The Harriet Lane Handbook, 15th edition, 2000 
† Reference – WHO Toxicity Grading Scale for Determining the Severity of Adverse Events 
 
 
TABLE D.   Guidelines for Grading of Laboratory Abnormalities 
 
 Grade 1 
MILD 
Grade 2 
MODERATE 
Grade 3 
SEVERE 
Grade 4 
LIFE-
THREATENING 
Haemoglobin 
(g/dL) 
9.0 – 9.9 7.0 – 8.9 5.0 – 6.9 < 5.0 
 
Reference – The Harriet Lane Handbook, 15th edition, 2000†  
Reference – WHO Toxicity Grading Scale for Determining the Severity of Adverse Events 
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APPENDIX I.    Weight-based administration of study medications 
 
Table 1. Weight-based administration for SP group 
Weight SP Placebo 
 Day 0 Day 0 Day 1 Day 2 
8 – 10 kg ½ ½ ½ ½ 
11 – 14 kg 1 ½ ½ ½ 
15 – 20 kg 1 1 1 1 
21 – 22 kg 1½ 1 1 1 
23 – 30 kg 1½ 1½ 1½ 1½ 
31 – 35 kg 2 1½ 1½ 1½ 
36 – 37 kg 2 2 2 2 
38 – 40 kg 2 2½ 2½ 2½ 
41 – 49 kg 3 2½ 2½ 2½ 
50 kg and over 3 3 3 3 
 
 
 
Table 2. Weight-based administration for AQ+SP group 
Weight SP AQ 
 Day 0 Day 0 Day 1 Day 2 
8 – 10 kg ½ ½ ½ ½ 
11 – 14 kg 1 ½ ½ ½ 
15 – 20 kg 1 1 1 1 
21 – 22 kg 1½ 1 1 1 
23 – 30 kg 1½ 1½ 1½ 1½ 
31 – 35 kg 2 1½ 1½ 1½ 
36 – 37 kg 2 2 2 2 
38 – 40 kg 2 2½ 2½ 2½ 
41 – 49 kg 3 2½ 2½ 2½ 
50 kg and over 3 3 3 3 
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Table 3.    Weight-based administration of study medications for DP group 
Weight 
(kg) 
Dihydroartemisinin-piperaquine (DP 40mg/320mg) 
 Day 0 Day 1 Day 2 Total DHA dose 
(mg/kg) 
Total PQ dose 
(mg/kg) 
5 ¼ ¼ ¼ 6.0 48.0 
6 ½ ½ ½ 10 80.0 
7 ½ ½ ½ 8.6 68.6 
8 ½ ½ ½ 7.5 60.0 
9 ½ ½ ½ 6.7 53.5 
10 ½ ½ ½ 6.0 48.0 
11 ¾  ¾ ¾ 8.2 65.5 
12 ¾  ¾ ¾ 7.5 60.0 
13 ¾  ¾ ¾ 6.9 55.4 
14 ¾  ¾ ¾ 6.4 51.4 
15 1 1 1 8.0 64.0 
16 1 1 1 7.5 60.0 
17 1 1 1 7.1 56.5 
18 1 1 1 6.7 53.3 
19 1 1 1 6.3 50.5 
20 1 ¼  1 ¼ 1 ¼ 7.5 60.0 
21 1 ¼  1 ¼ 1 ¼ 7.1 57.1 
22 1 ¼  1 ¼ 1 ¼ 6.8 54.5 
23 1 ¼  1 ¼ 1 ¼ 6.5 52.3 
24 1 ½ 1 ½ 1 ½ 7.5 60.0 
25 1 ½ 1 ½ 1 ½ 7.2 57.6 
26 1 ½ 1 ½ 1 ½ 6.9 55.4 
27 1 ½ 1 ½ 1 ½ 6.7 53.3 
28 1 ½ 1 ½ 1 ½ 6.4 51.4 
29 1 ¾  1 ¾ 1 ¾ 7.2 57.9 
30 1 ¾  1 ¾ 1 ¾ 7.0 56.0 
31 1 ¾  1 ¾ 1 ¾ 6.8 54.2 
32 1 ¾  1 ¾ 1 ¾ 6.6 52.3 
33 1 ¾  1 ¾ 1 ¾ 6.4 50.9 
34 2 2 2 7.1 56.5 
35 2 2 2 6.9 54.9 
36 2 2 2 6.7 53.3 
37 2 2 2 6.5 51.2 
38 2 2 2 6.3 50.5 
39 2 2 2 6.2 49.2 
40 2 2 2 6.0 48.0 
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Table 4. Weight-based administration for Placebo group 
Weight Placebo 
 Day 0 Day 1 Day 2 
8 – 10 kg ½ ½ ½ 
11 – 14 kg ½ ½ ½ 
15 – 20 kg 1 1 1 
21 – 22 kg 1 1 1 
23 – 30 kg 1½ 1½ 1½ 
31 – 35 kg 1½ 1½ 1½ 
36 – 37 kg 2 2 2 
38 – 40 kg 2½ 2½ 2½ 
41 – 49 kg 2½ 2½ 2½ 
50 kg and over 3 3 3 
 
UMSP IPT in schoolchildren study 
Completed by:____________________________________________________________ 
 
APPENDIX J: ACCEPTABILITY QUESTIONNAIRE 
Study  
Number:  |_____|_____|_____|_____|_____| 
Date: 
                             |____|____| / |____|____| / |____|____| 
                                    day               month            year 
 
I would like to ask you some questions about the 3-day treatment you received this week. 
 
 
1. How many tablets did you take at one time on the last day of treatment?                                                        
 
 
|____| full tablets 
 
|____| fractions 
 
  Don’t know 
 
 
2. What did you think about the taste of the tablets?                                                                      
 
  Poor       
 Fair                                                                                                  
  Good  
  Excellent 
  Don’t know 
 
 
3. How would you describe the taste of the tablets? 
Please describe 
 
 
4. What did you think about the color of the tablets? 
 
  Poor       
  Fair                                                                                                                                              
  Good  
  Excellent 
  Don’t know 
 
 
5. Did you have any problems during the 3 days that you received the treatment? 
 
  Yes  
  No 
  Don’t know 
 
 
6. If so, please describe the problems: 
 
 
 
 
 
7. Did you have any problems during the 4 days after you received the treatment? 
 
  Yes  
  No 
  Don’t know 
 
 
8. If so, please describe the problems: 
 
 
 
 
 
9. Would you be willing to take the tablets during every school term (three times a year)?                   
  Yes, very willing 
 Yes, willing 
  Don’t know 
  No, not willing 
  No, absolutely not 
 
 
10. Additional comments: 
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APPENDIX K. 
ADVERSE EVENT 
REPORT FORM 
Stude nt 
Initials: 
 
Study  
Number:  |_____|_____|_____|_____|_____| 
 
Date enrolled (Day 0): |____|____|/|____|____|/|____|____| 
                                               day              month              year 
 
 
 Complete on day first reported Complete on day first reported and update 
as needed 
Complete on final day 
Event description (a) Date o f event 
onset (b) 
Date event 
repo rted 
(c) 
Initials of 
person 
reporting 
Maximum 
severity* (d) 
Maximum 
relationship† (e) 
Serious? ‡  
(Y/N) 
(f) 
Episodic? 
(Y/N) 
(g) 
Outcome 
†† (h) 
Date event 
reso lved‡‡  
(i) 
1.          
2.          
3.          
4.          
5.          
6.          
7.          
8.          
9.          
10.          
11.          
12.          
13.          
14.          
15.          
 
* Severity: Rank on scale of 1-4:  mild = 1; moderate = 2; severe = 3, life-threatening = 4   
† Relationship:  Rank on scale of 0-4: none = 0; unlikely = 1; possible = 2; probable = 3; definite = 4    
‡ Serious: Criteria for SAE: fatal, life-threatening, results in or prolongs hospitalization, results in significant or persistent disability or capacity requires medical / surgical intervention to prevent serious 
outcome.   If serious, report to Kampala core facility staff immediately.   
††  Outcome: Rank on scale of 1-5: resolved without sequelae = 1; resolved with sequelae = 2; AE still present at study end/discontinuation, but improving = 3; subject died = 4; unknown = 5 
‡‡  Date event resolved: Complete on Day 42 –  If AE still ongoing at end of follow-up, indicate in question (h).  
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APPENDIX K.  
SERIOUS ADVERSE EVENT FORM 
– INITIAL REPORT (1) 
 
Date of SAE Report: 
 
                                 |____|____|/|____|____|/|____|____| 
                                       day               month            year  
 
 
Study  
Numbe r:  |_____|_____|_____|_____|_____| 
 
Date enrolled:  
                                 |____|____|/|____|____|/|____|____| 
                                       day               month            year  
 
 
Age :   |_____|_____|  years  
 
Gender:    
                     Male       Female 
 
 
Event 
description:__________________________________________________________________________________________________ 
                                  (symptom, sign, or laboratory abnormality) 
Date of event onset: 
 
|____|____|/|____|____|/|____|____| 
day               month            year  
 
Indicate reason for serious AE   
(tick all that apply): 
 
  Death 
  Life-threatening 
  Resulted in or prolonged hospitalization 
  Required medical / surgical intervention 
to prevent serious outcome 
  Resulted in sign ificant / persistent 
disability or incapacity 
 
  Other:____________________ 
 Date of site awareness: 
 
 
|____|____|/|____|____|/|____|____| 
day               month            year 
Maximum event severity: 
 
  Mild 
  Moderate 
  Severe 
  Life-threatening   
 
EVENT SUMMARY (include details of event, associated signs and symptoms, possible alternative etiologies, relevant past medical 
history, and medical management): 
______________________________________________________________________________________________________________ 
______________________________________________________________________________________________________________ 
______________________________________________________________________________________________________________ 
______________________________________________________________________________________________________________ 
______________________________________________________________________________________________________________ 
______________________________________________________________________________________________________________ 
______________________________________________________________________________________________________________ 
______________________________________________________________________________________________________________ 
______________________________________________________________________________________________________________ 
______________________________________________________________________________________________________________ 
 
Study product name:    BLINDED Route of study product:  ORAL 
Dosing schedule at SAE onset:     
 
Date study product first started (Day 0):              
 
                              |___|___|/|___|___|/|___|___|  
                                  day        month       year 
Date study product last taken prior to onset o f SAE: 
 
                |___|___|/|___|___|/|___|___| 
                    day        month       year 
Relationship to study product:  
              None 
        Unlikely 
        Possible 
        Probable 
        Definite 
 
If not asso ciated, is event related to : 
              Study procedure 
        Other condition or illness 
        Other medication 
        Other____________________________ 
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SERIOUS ADVERSE EVENT FORM – INITIAL REPORT (2) 
Date of SAE Report: 
 
                                 |____|____|/|____|____|/|____|____| 
                                       day               month            year  
 
 
Study  
Number:  |_____|_____|_____|_____|_____| 
 
Study product status: (tick all that apply) 
 
 No change in dose 
 Study treatment held 
 Study treatment discontinued permanently 
 Other____________________________________ 
 
 
Patient management: (tick all that apply) 
 
  Patient hospitalized 
  Blood transfusion given 
  Intravenous fluids given 
  Parenteral quinine given 
  Other____________________________________ 
  Other____________________________________ 
  Other____________________________________ 
 
RELEVANT LABORATORY TESTS 
Test Collection date 
(dd/mm/yy) 
Result Site normal 
range 
Mo st recent value 
prior to SAE 
Collection date 
(dd/mm/yy) 
  
|___ |___|/|___|___|/|___|___|     
    
|___ |___|/|___|___|/|___|___|     
  
|___ |___|/|___|___|/|___|___|     
    
|___ |___|/|___|___|/|___|___|     
  
|___ |___|/|___|___|/|___|___|     
    
|___ |___|/|___|___|/|___|___|     
  
|___ |___|/|___|___|/|___|___|     
    
|___ |___|/|___|___|/|___|___|     
RELEVANT DIAGNOSTIC TESTS 
Test Collection date 
(dd/mm/yy) 
Results/Comments 
  
|___ |___|/|___|___|/|___|___|     
 
  
|___ |___|/|___|___|/|___|___|     
 
  
|___ |___|/|___|___|/|___|___|     
 
CONCOMITANT MEDICATIONS (List relevant concomitant medications the subject was taking up to 1 month prior to SAE onset.) 
Medicatio n Start date 
(dd/mm/yy) 
Stop date 
(dd/mm/yy) 
To tal daily dose Indication Suspect  
 fo r 
SAE 
  
|___ |___|/|___|___|/|___|___|     
 
|___ |___|/|___|___|/|___|___|     
  
□  Yes 
□  No 
  
|___|___|/|___|___|/|___|___|     
 
|___ |___|/|___|___|/|___|___|     
  
□  Yes 
□  No 
  
|___|___|/|___|___|/|___|___|     
 
|___ |___|/|___|___|/|___|___|     
  
□  Yes 
□  No 
  
|___|___|/|___|___|/|___|___|     
 
|___ |___|/|___|___|/|___|___|     
  
□  Yes 
□  No 
  
|___|___|/|___|___|/|___|___|     
 
|___ |___|/|___|___|/|___|___|     
  
□  Yes 
□  No 
  
|___|___|/|___|___|/|___|___|     
 
|___ |___|/|___|___|/|___|___|     
  
□  Yes 
□  No 
Outcome of event: 
 
       Ongoing:  [SAE Follow Up Report to be completed and sent at later date] 
       Resolved without sequelae 
       Resolved with sequelae  _____________________________ 
       Death 
 
If resolved or died, indicate date: 
 
 
                 |___|___|/|___|___|/|___|___| 
                       day           month        year 
 
Completed by:  
Name printed:    ____________________________ Signature: ___________________________  Date: |___|___|/|___|___|/|___|___| 
                                                                                                                                                                                                         day            month           year 
Investigator’s  
Name printed:    ____________________________ Signature: ___________________________  Date: |___|___|/|___|___|/|___|___| 
                                                                                                                                                                                                         day          m onth            year 
 
